<?xml version="1.0" encoding="utf-8"?>
<resources xmlns:tools="http://schemas.android.com/tools">

    <string name="app_name">EP Mobile</string>
    <string name="about_text">EP Mobile is a package of
		useful cardiac electrophysiology
		tools for your Android phone or tablet.
		These tools are for reference purposes only
		and are not meant to substitute for clinical judgment.
		If you have suggestions or comments, please contact us.
		\n\nEmail: mannd@epstudiossoftware.com
        \nIcons: svgrepo.com
		\nWeb: www.epstudiossoftware.com
		\nSource: github.com/mannd/epmobile
		\n\nCopyright \u00a9 2011-2022 EP Studios, Inc.
		\nLicensed under GNU GPL v3.</string>
    <string name="main_index_title">EP Mobile</string>
    <string name="about_label">About</string>
    <string name="about_title">About EP Mobile</string>
    <string name="dofetilide_label">Dofetilide Calculator</string>
    <string name="dofetilide_calculator_title">Dofetilide Calculator</string>
    <string name="dabigatran_calculator_title">Dabigatran Calculator</string>
    <string name="dabigatran_label">Dabigatran Calculator</string>
    <string name="qtc_calculator_title">QTc Calculator</string>
    <string name="qtc_calculator_reference_bazett">Bazett H. C.
        An analysis of the time‐relations of electrocardiograms.
        Annals of Noninvasive Electrocardiology. 2006;2(2):177-194.</string>
    <string name="qtc_calculator_link_bazett">https://doi.org/10.1111/j.1542-474X.1997.tb00325.x</string>
    <string name="qtc_calculator_reference_fridericia">Fridericia LS.
        Die Systolendauer im Elektrokardiogramm bei normalen Menschen
        und bei Herzkranken. Acta Medica Scandinavica.
        1920;53(1):469-486.</string>
    <string name="qtc_calculator_link_fridericia">https://doi.org/10.1111/j.0954-6820.1920.tb18266.x</string>
    <string name="qtc_calculator_reference_sagie">Sagie A, Larson MG,
        Goldberg RJ, Bengtson JR, Levy D. An improved method for
        adjusting the QT interval for heart rate (the Framingham Heart Study).
        American Journal of Cardiology. 1992;70(7):797-801.</string>
    <string name="qtc_calculator_link_sagie">https://doi.org/10.1016/0002-9149(92)90562-D</string>
    <string name="qtc_calculator_reference_hodges">Hodges M, Salerno D,
        Erlinen D. Bazett’s QT correction reviewed: evidence that a linear
        QT correction for heart rate is better. J Am Coll Cardiol. 1983;1:694.</string>
    <string name="cycle_length_label">Interval/Rate Conversion</string>
    <string name="cycle_length_calculator_title">Interval/Rate Conversion</string>
    <string name="rr_hint">RR (msec)</string>
    <string name="interval_rate_title">Use RR Interval or Heart Rate</string>
    <string name="interval_rate_summary">Use RR interval or heart rate as default</string>
    <string name="qt_label">QT Interval (msec)</string>
    <string name="qt_hint">QT (msec)</string>
    <string name="qtc_result_label">QTc (msec)</string>
    <string name="qtc_formula_label">QTc Formula</string>
    <string name="calculate_label">Calculate</string>
    <string name="clear_label">Clear</string>
    <string name="dose_result_label">Dose</string>
    <string name="weight_hint">Weight (kg)</string>
    <string name="weight_lb_hint">Weight (lb)</string>
    <string name="creatinine_hint">Creatinine (mg/dL)</string>
    <string name="age_hint">Age (yr)</string>
    <string name="age_label">Age (yr)</string>
    <string name="male_label">Male</string>
    <string name="female_label">Female</string>
    <string name="cl_label">Interval to Rate</string>
    <string name="cl_hint">Interval (msec)</string>
    <string name="hr_label">Rate to Interval</string>
    <string name="hr_hint">Rate (bpm)</string>
    <string name="calculated_result_label"/>
    <string name="qtc_formula_title">Default QTc Formula</string>
    <string name="qtc_formula_summary">Select the default QTc formula</string>
    <string name="maximum_qtc_title">Maximum QTc</string>
    <string name="maximum_qtc_summary">Enter the maximum QTc in msec</string>
    <string name="maximum_qtc_message">This value in msec is used to
		color code (with red) abnormally high QTc values</string>
    <string name="maximum_qtc_default_value">440</string>
    <string name="settings_label">Settings</string>
    <string name="settings_title">EP Mobile Settings</string>
    <string name="hasbled_title">HAS-BLED Score</string>
    <string name="htn_label">Hypertension (systolic BP \u2267 160)</string>
    <string name="abnormal_renal_label">Abnormal renal function
		(dialysis, kidney transplant, Cr \u2267 2.6 mg/dL)</string>
    <string name="abnormal_liver_label">Abnormal liver function</string>
    <string name="stroke_label">Previous stroke history</string>
    <string name="bleeding_label">Major bleeding history</string>
    <string name="labile_inr_label">Labile INRs (high INRs, or &lt;60%
		of time in therapeutic range)</string>
    <string name="age65_label">Age 65 or over</string>
    <string name="drug_label">Taking antiplatelet drugs
		(e.g. ASA, Plavix)</string>
    <string name="etoh_label">Alcohol intake (8 or more drinks per week)</string>
    <string name="normal_hasbled">Low bleeding risk</string>
    <string name="abnormal_hasbled">High bleeding risk</string>
    <string name="chads_title">CHADS\u2082 Score</string>
    <string name="chf_label">Congestive heart failure</string>
    <string name="age75_label">Age 75 or over</string>
    <string name="diabetes_label">Diabetes mellitus</string>
    <string name="low_chads_message">Aspirin is recommended.</string>
    <string name="medium_chads_message">Aspirin or
		anticoagulation (warfarin, dabigatran, rivaroxaban, apixaban or edoxaban) is recommended.</string>
		<string name="high_chads_message">Anticoagulation (warfarin, dabigatran, rivaroxaban, apixaban or edoxaban) is recommended.</string>
    <string name="chads_proviso_message">Current guidelines recommend using CHA\u2082DS\u2082-VASc rather
        than CHADS\u2082 to assess stroke risk, especially when CHADS\u2082 is 0 or 1.</string>
    <string name="chadsvasc_title">CHA\u2082DS\u2082-VASc Score</string>
    <string name="vascular_label">Vascular disease (e.g. PVD, CAD, aortic plaque)</string>
    <string name="low_chadsvasc_message">No antithrombotic therapy is reasonable.</string>
    <string name="medium_chadsvasc_message">No anticoagulation or anticoagulation (warfarin, dabigatran, rivaroxaban, apixaban
        or edoxaban) or aspirin may be considered (2014 AHA/ACC/HRS guidelines).
    </string>
    <string name="high_chadsvasc_message">Anticoagulation
    (warfarin, dabigatran, rivaroxaban, apixaban or edoxaban) is recommended.</string>
    <string name="female_only_chadsvasc_message">European Society of Cardiology (2012) recommends no anticoagulation when female sex is
        the only risk factor.</string>
    <string name="non_female_chadsvasc_message">European Society of Cardiology (2012) recommends anticoagulation.</string>
    <string name="warfarin_title">Warfarin Clinic</string>
    <string name="warfarin_label">Warfarin Dose Calculator</string>
    <string name="tablet_label">Tablet</string>
    <string name="tablet1">1 mg</string>
    <string name="tablet2">2 mg</string>
    <string name="tablet3">2.5 mg</string>
    <string name="tablet4">3 mg</string>
    <string name="tablet5">4 mg</string>
    <string name="tablet6">5 mg</string>
    <string name="tablet7">6 mg</string>
    <string name="tablet8">7.5 mg</string>
    <string name="tablet9">10 mg</string>
    <string name="inr_label">Current INR</string>
    <string name="weekly_dose_label">Current Dose (mg/wk)</string>
    <string name="inr_hint">INR</string>
    <string name="weekly_dose_hint">Dose (mg/wk)</string>
    <string name="inr_target_label">INR Target</string>
    <string name="inr_target1">2.0 – 3.0</string>
    <string name="inr_target2">2.5 – 3.5</string>
    <string name="default_warfarin_tablet_title">Default Warfarin Tablet</string>
    <string name="default_warfarin_tablet_summary">Select the default warfarin tablet strength</string>
    <string name="default_inr_target_title">Default INR Target</string>
    <string name="default_inr_target_summary">Default INR target range</string>
    <string name="dose_table_title">Suggested Weekly Warfarin Doses</string>
    <string name="warfarin_result_title">Suggested Warfarin Dosing</string>
    <string name="warfarin_reference">Horton JD, Bushwick BM.
        Warfarin Therapy: Evolving Strategies in Anticoagulation.
        afp. 1999;59(3):635-646.</string>
    <string name="warfarin_link">https://www.aafp.org/pubs/afp/issues/1999/0201/p635.html</string>
    <string name="wct_algorithm_list_title">Wide Complex Tachycardia</string>
    <string name="wct_algorithm_title">Wide Complex Tachycardia</string>
    <string name="brugada_vt_title">Brugada Criteria SVT vs VT</string>
    <string name="brugada_wct_title">Brugada Algorithm</string>
    <string name="brugada_step_1">Absence of an RS complex in all precordial leads?</string>
    <string name="brugada_step_2">R to S interval > 100 msec in one precordial lead?</string>
    <string name="brugada_step_3">AV dissociation?</string>
    <string name="brugada_step_4">Morphology criteria for VT present in both
		precordial leads V1-2 and V6?</string>
    <string name="vt_result">Wide complex tachycardia is most likely Ventricular
		Tachycardia.</string>
    <string name="svt_result">Wide complex tachycardia is most likely
		Supraventricular Tachycardia.</string>
    <string name="brugada_reference">Reference: Brugada P, et al. Circ 1991;83:1649.</string>
    <string name="wct_result_label">WCT Result</string>
    <string name="yes">Yes</string>
    <string name="no">No</string>
    <string name="back">Back</string>
    <string name="done_label">Done</string>
    <string name="reset_label">Reset</string>
    <string name="dont_reset_label">Don\'t Reset</string>
    <string name="copy_report_label">Copy</string>
    <string name="dosing_label">Dosing</string>
    <string name="morphology_label">Morphology Criteria</string>
    <string name="morphology_title">@string/morphology_label</string>
    <string name="broad_r">R > 30 msec in V1 or V2</string>
    <string name="broad_rs">Onset to nadir S > 60 msec in V1 or V2</string>
    <string name="notched_s">Notched or slurred S in V1 or V2</string>
    <string name="q_v6">QR or QS in V6</string>
    <string name="monophasic_r_v1">Monophasic R in V1</string>
    <string name="qr_v1">QR in V1</string>
    <string name="rs_v1">RS in V1</string>
    <string name="deep_s_v6">R to S ratio &lt; 1 in V6</string>
    <string name="monophasic_r_v6">Monophasic R in V6</string>
    <string name="rwpt_title">R Wave Peak Time Criterion</string>
    <string name="rwpt_text">R wave peak time in lead II (RWPT).
		Measure the onset of the QRS in ECG lead II to the first
		change in polarity (nadir Q or peak R). RWPT \u2265 50 msec
		strongly suggests VT (positive likelihood ratio 34.8).
		Reference: Pava LF, et al. Heart Rhythm 2010;7:922.</string>
    <string name="rbbb_wct_label">"RBBB" Tachycardia</string>
    <string name="lbbb_wct_label">"LBBB" Tachycardia</string>
    <string name="wellens_reference">From Wellens et al. Am J Med 1978;64:27.</string>
    <string name="normal_ep_values_title">Normal EP Values</string>
    <string name="basic_intervals_label">Basic Conduction Intervals</string>
    <string name="sinus_node_label">Sinus Node Function</string>
    <string name="refractory_periods_label">Refractory Periods and Block Cycle Lengths</string>
    <string name="normal_ep_values_reference">Reference: Josephson ME. Clinical Cardiac
		Electrophysiology. Techniques and Interpretations. 2nd Edition 1993.
		Lea &amp; Febiger.</string>
    <string name="arvc_2010_criteria_title">ARVC/D Diagnosis (2010)</string>
    <string name="global_dysfunction_label">I. Global or regional dysfunction and structural
		alterations</string>
    <string name="major">MAJOR</string>
    <string name="minor">MINOR</string>
    <string name="by_echo_label">By 2D echo:</string>
    <string name="regional_echo_abnormality_label">Regional RV akinesia, dyskinesia, or aneurysm</string>
    <string name="regional_echo_minor_abnormality_label">Regional RV akinesia or dyskinesia</string>
    <string name="regional_mri_abnormality_label">Regional RV akinesia or dyssynchronous RV
		contraction</string>
    <string name="and_one_echo_label">and one of the following (end diastole)…</string>
    <string name="and_one_label">and one of the following…</string>
    <string name="major_plax_criteria">PLAX RVOT \u2265 32 mm (corrected for body size
		[PLAX/BSA] \u2265 19 mm/m\u00b2)</string>
    <string name="major_psax_criteria">PSAX RVOT \u2265 36 mm (corrected for body size
		[PSAX/BSA] \u2265 21 mm/m\u00b2)</string>
    <string name="fractional_area_criteria">fractional area change \u2264 33%</string>
    <string name="minor_plax_criteria">PLAX RVOT \u2265 29 to \u003c 32 mm (corrected for
		body size
		[PLAX/BSA] \u2265 16 to \u003c 19 mm/m\u00b2)</string>
    <string name="minor_psax_criteria">PSAX RVOT \u2265 32 to \u003c 36mm (corrected for
		body size
		[PSAX/BSA] \u2265 18 to \u003c 21 mm/m\u00b2)</string>
    <string name="fractional_area_minor_criteria">fractional area change \u003e 33%
		and \u2264 40%</string>
    <string name="by_mri_label">By MRI:</string>
    <string name="major_mri_volume_criteria">Ratio of RV end-diastolic volume to BSA \u2265 110
		mL/m\u00b2
		(male) or \u2265 100 mL/m\u00b2 (female)</string>
    <string name="major_mri_ef_criteria">RV ejection fraction \u2264 40%</string>
    <string name="minor_mri_volume_criteria">Ratio of RV end-diastolic volume to BSA \u2265 100
		to
		\u003c 110 mL/m\u00b2 (male) or \u2265 90 to \u003c 100 mL/m\u00b2 (female)</string>
    <string name="minor_mri_ef_criteria" formatted="false">RV ejection fraction \u003e 40% to \u2264 45%</string>
    <string name="by_rv_angio_label">By RV Angiography:</string>
    <string name="tissue_label">II. Tissue characterization of wall</string>
    <string name="major_residual_myocytes_label" formatted="false">Residual myocytes \u003c 60% by morphometric
		analysis (or \u003c 50% if estimated) with fibrous replacement of RV
		free wall myocardium in \u2265 1 sample, with or without fatty
		replacement of tissue on endomyocardial biopsy</string>
    <string name="minor_residual_myocytes_label" formatted="false">Residual myocytes 60% to 75% by morphometric
		analysis (or 50% to 65% if estimated) with fibrous replacement of RV
		free wall myocardium in \u2265 1 sample, with or without fatty
		replacement of tissue on endomyocardial biopsy</string>
    <string name="repolarization_label">III. Repolarization abnormalities</string>
    <string name="major_repolarization_label">TWI (V1, V2, and V3) or beyond in
	individuals \u003e 14 yrs (in absence of complete RBBB)</string>
    <string name="minor_repolarization_no_rbbb_label">TWI in V1 and V2
	in individuals \u003e 14 yrs (in absence of complete RBBB) or in V4, V5, V6</string>
    <string name="minor_repolarization_rbbb_label">TWI in V1-V4 in
	individuals \u003e 14 yrs in presence of complete RBBB</string>
    <string name="depolarization_label">IV. Depolarization/conduction abnormalities</string>
    <string name="major_depolarization_label">Epsilon wave (reproducible low-amp signals between
	end of QRS complex to onset of T wave) in right precordial leads (V1-V3)</string>
    <string name="saecg_label">LP by SAECG in \u2265 1 of 3 parameters in 
	absence of QRS duration of \u2265 110 msec on standard ECG</string>
    <string name="filtered_qrs_label">Filtered QRS duration (fQRS) \u2265 114 msec</string>
    <string name="duration_terminal_qrs_label">Duration of terminal QRS \u003c 40 \u03bcV
	(low-amplitude signal duration) \u2265 38 msec</string>
    <string name="root_mean_square_label">Root-mean-square voltage of terminal 40 msec \u2264 20 \u03bcV</string>
    <string name="terminal_activation_label">Terminal activation duration</string>
    <string name="terminal_activation_duration_label">Terminal activation duration of QRS
	\u2265 55 msec measured from the nadir of the S wave to the end of the QRS including
	R\', in V1, V2, or V3, in the absence of complete RBBB</string>
    <string name="arrhythmias_label">V. Arrhythmias</string>
    <string name="major_arrhythmias_label">Nonsustained or sustained VT of LBBB morphology
	with superior axis (negative or indeterminate QRS in leads II, III, and aVF and
	positive in lead aVL)</string>
    <string name="rvot_vt_label">Nonsustained or sustained VT of RV outflow configuration,
	LBBB morphology with inferior axis (positive QRS in leads II, III, and aVF and negative
	in lead aVL) or of unknown axis</string>
    <string name="pvcs_label">\u003e 500 ventricular extrasystoles per 24 hours (Holter)</string>
    <string name="family_history_label">VI. Family history</string>
    <string name="first_degree_relative_label">ARVC/D confirmed in a first-degree relative
	who meets current Task Force criteria</string>
    <string name="pathology_label">ARVC/D confirmed pathologically at autopsy or surgery 
	in a first-degree relative</string>
    <string name="genetic_label">Identification of a pathogenic mutation categorized
	as associated or probably associated with ARVC/D in the patient under evaluation</string>
    <string name="possible_family_history_label">History of ARVC/D in a first-degree
	relative in whom it is not possible or practical to determine whether the family
	member meets current Task Force criteria</string>
    <string name="family_history_sudden_death_label">Premature sudden death (\u003c 35
	years of age) due to suspected ARVC/D in a first-degree relative</string>
    <string name="second_degree_relative_label">ARVC/D confirmed pathologically or by 
	current Task Force Criteria in a second-degree relative</string>
    <string name="arvc_2010_key">BSA = body surface area.
        \nPLAX = parasternal long axis view.
        \nPSAX = parasternal short axis view.
        \nRVOT = RV outflow tract.</string>
    <string name="arvc_reference_2010">Marcus FI, McKenna WJ, Sherrill D, et al.
        Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia:
        Proposed Modification of the Task Force Criteria. European Heart Journal.
        2010;31(7):806-814.</string>
    <string name="arvc_link_2010">https://doi.org/10.1093/eurheartj/ehq025</string>
    <string name="qtc_settings">QTc Calculator Settings</string>
    <string name="warfarin_settings">Warfarin Settings</string>
    <string name="creatinine_clearance_instructions">This calculator and all the drug
        calculators (except Warfarin) use the Cockcroft-Gault formula, which is the recommended
        formula for calculating creatinine clearance for determining drug doses.  You can consider
        using the Weight Calculator to adjust body weight for determining
        creatinine clearance.\n\nIf you wish to calculate a normalized GFR to estimate
        renal function, use the GFR Calculator instead.
    </string>
    <string name="creatinine_clearance_reference">Cockcroft DW, Gault H.
        Prediction of Creatinine Clearance from Serum Creatinine.
        NEF. 1976;16(1):31-41.</string>
    <string name="creatinine_clearance_link">https://doi.org/10.1159/000180580</string>
    <string name="drug_calculator_instructions">The drug calculators use the
        Cockcroft-Gault formula for determining creatinine clearance, and the formulas
        used are derived from the drug package inserts.  See the Drug Reference module
        in the Reference and Tools section of the app.  Also, consider using the
        Weight Calculator to adjust the weight to better estimate creatinine clearance</string>
    <string name="drug_calculator_settings">Other Calculator Settings</string>
    <string name="default_weight_unit_title">Default Weight Unit</string>
    <string name="default_weight_unit_summary">Select default unit for weight</string>
    <string name="creatinine_clearance_label"/>
    <string name="long_creatinine_clearance_label">Creatinine Clearance</string>
    <string name="dabigatran_warning_severe">Avoid concomitant use of P-gp inhibitors
	    (e.g. dronedarone).</string>
    <string name="dabigatran_warning_mild">Consider reducing dose of dabigatran to 75 mg twice a day 
	    when dronedarone or systemic ketoconazole is administered with dabigatran.</string>
    <string name="dabigatran_warning_75_years_old">There may be increased bleeding risk at age over 75 years.</string>
    <string name="rivaroxaban_calculator_title">Rivaroxaban Calculator</string>
    <string name="rivaroxaban_dosing_message">Take dose with evening meal.</string>
    <string name="icd_calculator_title">CMS ICD Criteria (2018)</string>
    <string name="short_qt_title">Short QT Syndrome Diagnosis</string>
    <string name="qtc_label">QTc Interval</string>
    <string name="short_qt_label">\u003c 370 msec</string>
    <string name="shorter_qt_label">\u003c 350 msec</string>
    <string name="shortest_qt_label">\u003c 330 msec</string>
    <string name="jt_label">Jpoint-Tpeak Interval</string>
    <string name="short_jt_label">\u003c 120 msec</string>
    <string name="clinical_history_label">Clinical History</string>
    <string name="sudden_cardiac_arrest_label">Sudden cardiac arrest</string>
    <string name="polymorphic_vt_label">Polymorphic VT or VF</string>
    <string name="unexplained_syncope_label">Unexplained syncope</string>
    <string name="afb_label">Atrial fibrillation</string>
    <string name="family_hx_label">Family History</string>
    <string name="relative_with_sqts_label">1st or 2nd degree relative with SQTS</string>
    <string name="relative_with_sd_label">1st or 2nd degree relative with sudden death</string>
    <string name="sids_label">Sudden infant death syndrome</string>
    <string name="genotype_label">Genotype</string>
    <string name="genotype_positive_label">Genotype positive</string>
    <string name="mutation_label">Mutation of undetermined significance
	    in a culprit gene</string>
    <string name="sqts_reference">Gollob M, et al. J Am Coll Cardiol 2011;57:802.</string>
    <string name="instructions_label">Instructions</string>
    <string name="sqts_instructions">Electrocardiogram must be recorded in the absence of modifiers
	    known to shorten the QT.  Jpoint-Tpeak interval must be measured in the precordial lead
	    with the greatest amplitude T-wave.  Clinical history: events must occur in the absence of
	    an identifiable etiology, including structural heart disease.  Note that at least one ECG
	    manifestation must be present in order to get additional points.</string>
    <string name="drug_dose_calculator_list_title">Drug Dose Calculators</string>
    <string name="drug_dose_calculators_title">Drug Dose Calculators</string>
    <string name="risk_score_list_title">Risk Scores</string>
    <string name="risk_scores_title">Risk Scores</string>

    <!-- HCM -->
    <string name="hcm_title">HCM SCD Risk (2002)</string>
    <!-- Major risk factors -->
    <string name="cardiac_arrest_label">Cardiac arrest (VF)</string>
    <string name="spontaneous_vt_label">Spontaneous sustained VT</string>
    <string name="family_hx_sd_label">Family history of premature SD</string>
    <!-- unexplained_syncope_label -->
    <string name="lv_thickness_label">LV thickness \u2265 30 mm</string>
    <string name="abnormal_exercise_bp_label">Abnormal exercise BP</string>
    <string name="nonsustained_vt_label">Nonsustained VT (Holter)</string>
    <!-- Minor risk factors -->
    <!-- afb_label -->
    <string name="myocardial_ischemia_label">Myocardial ischemia</string>
    <string name="lv_outflow_obstruction_label">LV outflow obstruction</string>
    <string name="high_risk_mutation_label">High-risk mutation</string>
    <string name="hcm_highest_risk_sd_text">Survivors of cardiac arrest and patients
	    with spontaneous sustained VT are considered at very high risk for SD and are
	    ICD candidates</string>
    <string name="hcm_high_risk_text">Patients with 2 or more major risk factors are
	    considered at high risk and should be considered for ICD implantation.</string>
    <string name="hcm_intermediate_risk_text">Patients with 1 major risk factor have 
	    increased risk for SD and recommendations should be individualized.
	    Factors such as the nature of the risk factor (e.g. SD in an immediate family
	    member with HCM), young age (which confers greater risk) and presence of minor risk
	    factors should be considered.  ICD implantation can be considered depending
	    on these factors.</string>
    <string name="hcm_low_risk_text">Patients without any major risk factors (even if
	    minor risk factors are present) are considered to be at low risk for SD.
	    ICD implantation is not recommended.</string>
    <string name="hcm_key">BP = blood pressure. VF = ventricular fibrillation.  VT = ventricular tachycardia.
	    SD = unexpected sudden death.  Abnormal exercise BP = failure to augment and maintain systolic
	    BP \u003e 25 mm Hg with exercise.</string>
    <string name="hcm_reference">References: Maron B et al.  Eur Heart J 2003:1965.
	    http://eurheartj.oxfordjournals.org/content/24/21/1965.full
	    McKenna WJ et al. Heart 2002;87:169.
	    http://heart.bmj.com/content/87/2/169.full</string>

    <!-- ICD CMS criteria -->
    <string name="secondary_prevention_label">Secondary Prevention</string>
    <string name="icd_cardiac_arrest_label">Documented CA due to VF, without transient or reversible cause</string>
    <string name="icd_sus_vt_label">Documented sustained VT/VF, either spontaneous or induced at EPS, not associated with an acute MI, 
	     and without transient or reversible cause</string>
    <string name="primary_prevention_label">Primary Prevention</string>
    <string name="icd_familial_conditions_label">Documented familial or inherited condition 
        with a high risk of life-threatening VT, including, but not limited to, Long QT Syndrome or HCM</string>
    <string name="icd_nonischemic_cm_label">Nonischemic cardiomyopathy on OMT \u2265 3 months</string>
    <string name="icd_ischemic_cm_label">Ischemic cardiomyopathy</string>
    <string name="icd_ef_gt_35_label">EF \u003e 35%</string>
    <string name="icd_ef_lt_35_label">EF \u003e 30% and \u2264 35%</string>
    <string name="icd_ef_lt_30_label">EF \u2264 30%</string>
    <string name="icd_mi_label">Prior MI</string>
    <string name="icd_nyha1_label">NYHA class I</string>
    <string name="icd_nyha2_label">NYHA class II</string>
    <string name="icd_nyha3_label">NYHA class III</string>
    <string name="icd_nyha4_label">NHYA class IV</string>
    <string name="exclusions_label">Exclusion</string>
    <string name="icd_cardiogenic_shock_label">Not clinically stable (e.g. in shock, from any etiology)</string>
    <string name="icd_recent_cabg_label">CABG or PCI within past 3 months</string>
    <string name="icd_recent_mi_label">Acute MI within past 40 days</string>
    <string name="icd_revascularization_candidate_label">Symptoms or findings that would make patient a candidate for revascularization</string>
    <string name="icd_brain_damage_label">Significant, irreversible brain damage</string>
    <string name="icd_svt_uncontrolled_rate_label">SVT, e.g. AF, with poorly controlled ventricular rate</string>
    <string name="icd_bad_prognosis_label">Non-cardiac disease with likelihood of survival \u003c 1 year</string>
    <string name="icd_no_nyha_message">You must select a NYHA class.</string>
    <string name="icd_approved_text">ICD implantation appears to meet CMS guidelines.</string>
    <string name="icd_not_approved_text">ICD implantation does NOT meet CMS guidelines.</string>
    <string name="absolute_exclusion">There are one or more absolute exclusions to ICD implantation.</string>
    <string name="cms_icd_instructions">Select patient characteristics and then select Calculate
        to show whether the patient is likely to meet CMS guidelines for Medicare reimbursement.
        Note the CMS National Coverage Determination
        (NCD) is quite detailed and you should be very familiar with it before making a decision
        as to whether a particular patient is covered.
        This module is only intended as a guide to the NCD and is not definitive.
        The module has been updated to the latest 2018 CMS guidelines.</string>
    <string name="cms_icd_key">AF = atrial fibrillation.\nCA
        = cardiac arrest.\nCABG
        = coronary artery bypass grafting.\nCM
        = cardiomyopathy.\nCMS
        = Centers for Medicare and Medicaid Services.\nEF
        = ejection fraction.\nEPS
        = electrophysiology study.\nHCM
        = hypertrophic cardiomyopathy.\nICD
        = implantable cardioverter defibrillator.\nOMT
        = optimal medical therapy.\nMI
        = myocardial infarction.\nNYHA
        = New York Heart Association.\nPCI
        = percutaneous coronary intervention.\nSVT
        = supraventricular tachycardia.\nVT
        = ventricular tachycardia/tachyarrhythmia.\nVF
        = ventricular fibrillation.\n</string>
    <string name="cms_icd_reference">CMS: Decision Memo for Implantable Cardioverter Defibrillators (CAG-00157R4) Feb 15, 2018.</string>
    <string name="cms_icd_link">https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=288</string>
    <string name="cms_icd_shared_decision_message">Shared decision making encounter using evidence-based decision tool
        necessary prior to ICD implant.</string>
    <string name="hemorrhages_title">HEMORR\u2082HAGES Score</string>
    <string name="low_risk_hemorrhages">Low risk of bleeding.</string>
    <string name="intermediate_risk_hemorrhages">Intermediate risk of bleeding.</string>
    <string name="high_risk_hemorrhages">High risk of bleeding.</string>
    <string name="hemorrhages_reference">Gage BF et al. Am Heart J 2006;151:713</string>
    <string name="hepatic_or_renal_disease_label">Hepatic (cirrhosis, \u2265 2-fold
        elevation of AST or ALT, or albumin &lt; 3.6 g/dL) or renal disease (Cr clearance &lt; 30 mL/min)</string>
    <string name="etoh_hemorrhages_label">Ethanol use (history of EtOH abuse, recent hospitalization for EtOH-related illness, and
	    worsening liver disease</string>
    <string name="malignancy_label">Malignancy (recent metastatic cancer)</string>
    <string name="older_label">Older (age > 75)</string>
    <string name="platelet_label">Reduced platelet count or function (plts &lt; 75,000, scheduled use of antiplatelet
	    therapy, i.e. daily ASA or NSAID Rx, or blood dyscrasia)</string>
    <string name="rebleeding_label">Re-bleeding (prior bleed requiring hospitalization)</string>
    <string name="htn_uncontrolled_label">Hypertension, uncontrolled (BP not currently controlled, 
	    systolic BP \u2265 160)</string>
    <string name="anemia_label">Anemia (most recent Hct &lt; 30 or Hgb &lt; 10 g/dL)</string>
    <string name="genetic_factors_label">Genetic factors (CYP2C9*2 and/or CYP2C9*3)</string>
    <string name="fall_risk_label">Elevated risk of fall including neuropsychiatric disease (Alzheimer, Parkinson,
	    schizophrenia, etc.)</string>
    <string name="stroke_hemorrhages_label">Stroke</string>
    <string name="wpw_algorithm_title">WPW Pathway Location</string>
    <string name="wpw_algorithm_list_title">WPW Pathway Location</string>
    <string name="arruda_title">Arruda Algorithm</string>
    <string name="modified_arruda_title">Modified Arruda Algorithm</string>
    <string name="milstein_title">Milstein Algorithm</string>
    <string name="arruda_step_1">Note this algorithm uses polarity of initial delta
        wave (positive +, negative -, or isoelectric \u00b1)\n\nLead I delta \u00b1 or -\n or V1 R/S \u2265 1?</string>
    <string name="arruda_step_2_3">Pathway is Left Free Wall\nLead aVF delta + ?</string>
    <string name="arruda_step_6_7">Pathway is Left Free Wall\nLead I delta \u00b1 or Lead V1 S \u00b1 ?</string>
    <string name="arruda_step_8a">Lead V1 delta + ?</string>
    <string name="arruda_step_8b">Lead V1 delta \u00b1 ?</string>
    <string name="arruda_step_13">Lead II delta - ?</string>
    <string name="arruda_step_15">Lead V1 delta \u00b1 or - ?</string>
    <string name="arruda_step_16_17">Pathway is Septal\nLead aVF delta - ?</string>
    <string name="arruda_step_18">Lead aVF delta \u00b1 ?</string>
    <string name="arruda_step_20">Lead III R \u2265 S ?</string>
    <string name="arruda_step_24_25_26">Pathway is Right Free Wall\nLead aVF delta + ?</string>
    <string name="arruda_step_27">Lead II delta + ?</string>
    <string name="pathway_location_label">Accessory Pathway Location</string>
    <string name="show_map_label">Show Map</string>
    <string name="lpl_ll_location">Left Posterolateral or Left Lateral</string>
    <string name="ll_location">Left Lateral</string>
    <string name="lal_location">Left Anterolateral</string>
    <string name="lp_psta_location">Left Posterior or Posteroseptal Tricuspid Annulus</string>
    <string name="lp_lpl_location">Left Posterior or Left Posterolateral</string>
    <string name="ll_lal_location">Left Lateral or Left Anterolateral</string>
    <string name="subepicardial_location">Epicardial: Coronary Sinus or Middle Cardiac Vein</string>
    <string name="psta_psma_location">Posteroseptal Tricuspid Annulus or Posteroseptal Mitral Annulus</string>
    <string name="as_location">Anteroseptal</string>
    <string name="psta_location">Posteroseptal Tricuspid Annulus</string>
    <string name="msta_location">Mid-septal Tricuspid Annulus</string>
    <string name="rp_rpl_location">Right Posterior or Right Posterolateral</string>
    <string name="ra_ral_location">Right Anterior or Right Anterolateral</string>
    <string name="rl_location">Right Lateral</string>
    <string name="undetermined_location">Undetermined Location</string>
    <string name="av_annulus_map_title">Accessory Pathway Location</string>
    <string name="milstein_step_1">Q or isoelectric delta wave in Leads I, aVL, or V6?</string>
    <string name="milstein_step_2_5">LBBB (+ QRS \u2265 90 msec in Lead I and rS in V1 and V2)?</string>
    <string name="milstein_step_3">Q or isoelectric delta wave two of Leads II, III, aVF?</string>
    <string name="milstein_step_4">Rs or RS in V1, V2, or V3?</string>
    <string name="milstein_step_6">QRS axis \u003e +30\u00b0?</string>
    <string name="milstein_step_7">Rs or RS in V1 or V2?</string>
    <string name="anatomy_av_annulus_title">Anatomy of AV Annulus</string>
    <!-- Long QT -->
    <string name="long_qt_syndrome_diagnosis_title">Long QT Syndrome Diagnosis</string>
    <string name="ecg_findings_label">ECG Findings</string>
    <string name="longest_qt_label">QTc \u2265 480 msec</string>
    <string name="longer_qt_label">QTc 460–479 msec</string>
    <string name="long_qt_label">QTc 450–459 msec (in males)</string>
    <string name="long_qt_post_exercise_label">QTc 4th min of recovery from exercise stress test
        \u2265 480 msec</string>
    <string name="torsade_label">Torsade de pointes</string>
    <string name="t_wave_alternans_label">T wave alternans</string>
    <string name="notched_t_wave_label">Notched T wave in 3 leads</string>
    <string name="low_hr_label">Low heart rate for age*</string>
    <string name="clinical_hx_label">Clinical History</string>
    <string name="syncope_with_stress_label">Syncope with stress</string>
    <string name="syncope_without_stress_label">Syncope without stress</string>
    <string name="congenital_deafness_label">Congenital deafness</string>
    <string name="family_hx_lqt_label">Family members with definite LQTS</string>
    <string name="family_hx_scd_label">Unexplained SCD \u003c age 30 in immediate family</string>
    <string name="lqts_key">ECG findings in absence of medications that affect ECG, 
        LQTS = long QT syndrome, QTc calculated by Bazett formula,
        SCD = sudden cardiac death, *resting heart rate below 2nd percentile for age.
        Note: the same family member cannot be counted more than once.</string>
    <string name="lqts_reference">Schwartz PJ et al.  Circulation 2011;124:2181.
        http://circ.ahajournals.org/content/124/20/2181</string>
    <!-- ARVC 1994 criteria -->
    <string name="arvc_old_criteria_title">ARVC/D Diagnosis (1994)</string>
    <string name="arvc_old_rv_dilatation">Severe dilatation and reduction
        of RVEF with no or only mild LV impairment</string>
    <string name="arvc_old_rv_aneurysms">Localized RV aneurysms (akinetic
        or dyskinetic areas with diastolic bulging)</string>
    <string name="arvc_old_rv_segmental_dilatation">Severe segmental dilatation
	    of the RV</string>
    <string name="arvc_old_mild_rv_dilatation">Mild global RV dilatation and/or
	    EF reduction with normal LV</string>
    <string name="arvc_old_mild_rv_segmental_dilatation">Mild segmental dilatation of
	    the RV</string>
    <string name="arvc_old_regional_rv_hypokinesia">Regional RV hypokinesia</string>
    <string name="arvc_old_fatty_replacement">Fibrofatty replacement of myocardium
	    on endomyocardial biopsy</string>
    <string name="arvc_old_twi"> T wave inversion in leads V2 and V3,
	    with age \u003e 12 yrs, in absence of RBBB</string>
    <string name="arvc_old_epsilon_waves">Epsilon waves or localized prolongation
	    (> 110 msec) of QRS complex in leads V1 to V3</string>
    <string name="arvc_old_late_potentials">Late potentials on SAECG</string>
    <string name="arvc_old_lbbb">Sustained or nonsustained ventricular tachycardia
	    with LBBB morphology on ECG, Holter or treadmill test</string>
    <string name="arvc_old_pvcs">> 1000 ventricular extrasystoles per 24 hours</string>
    <string name="arvc_old_familial_disease">Familial ARVC/D confirmed at
	    autopsy or surgery</string>
    <string name="arvc_old_family_hx_scd">Family history of sudden death
	    (&lt; 35 yrs) due to suspected ARVC/D</string>
    <string name="arvc_old_family_hx">Family history of ARVC/D based on these
	    criteria</string>
    <string name="arvc_old_reference">McKenna WJ, Thiene G, Nava A, et al.
        Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy.
        Task Force of the Working Group Myocardial and Pericardial Disease
        of the European Society of Cardiology and of the Scientific Council on
        Cardiomyopathies of the International Society and Federation of
        Cardiology. Br Heart J. 1994;71(3):215-218.</string>
    <string name="arvc_old_link">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC483655/</string>
    <!-- LVH -->
    <string name="lvh_list_title">Left Ventricular Hypertrophy</string>
    <string name="lvh_title">Left Ventricular Hypertrophy</string>
    <string name="estes_criteria_title">Romhilt-Estes LVH Score</string>
    <string name="other_lvh_criteria_title">LVH Voltage Criteria</string>
    <string name="sokolow_label">Sokolow-Lyon Index</string>
    <string name="sokolow_s_plus_r_label">S in V1 + R in V5 or V6</string>
    <string name="sokolow_s_plus_r_result">\u2265 35 mm</string>
    <string name="sokolow_r_in_avl_label">R in aVL</string>
    <string name="sokolow_r_in_avl_result">\u2265 11 mm</string>
    <string name="cornell_label">Cornell Voltage Criteria</string>
    <string name="cornell_men_label">S in V3 + R in aVL (men)</string>
    <string name="cornell_men_result">> 28 mm</string>
    <string name="cornell_women_label">S in V3 + R in aVL (women)</string>
    <string name="cornell_women_result">> 20 mm</string>
    <string name="other_voltage_criteria_label">Minnesota Code 3.1</string>
    <string name="other_lvh_lead_i_label">R in I, II, III, or aVF</string>
    <string name="other_lvh_lead_i_result">> 20 mm</string>
    <string name="other_lvh_lead_avl_label">R in aVL</string>
    <string name="other_lvh_lead_avl_result">> 12 mm</string>
    <string name="other_lvh_lead_v5_label">R in V5 or V6</string>
    <string name="other_lvh_lead_v5_result">> 26 mm</string>
    <string name="other_lvh_key">LVH present if any of above voltage criteria met.</string>
    <string name="other_lvh_reference">Reference: Hsieh BP et al. Am Heart J 2005;150:161.</string>
    <string name="estes_voltage_label">Any limb-lead R or S \u2265 20 mm
        or S V1 or V2 \u2265 30 mm or R V5 or V6 \u2265 30 mm</string>
    <string name="estes_strain_without_dig_label">Left ventricular strain pattern without digitalis</string>
    <string name="estes_strain_with_dig_label">Left ventricular strain pattern with digitalis</string>
    <string name="estes_lae_label">Left atrial enlargement</string>
    <string name="estes_lad_label">Left axis deviation \u2265 -30\u00b0</string>
    <string name="estes_qrs_duration_label">QRS duration \u2265 90 msec</string>
    <string name="estes_intrinsicoid_label">Intrinsicoid QRS deflection of \u2265 50 msec in V5 or V6</string>
    <string name="estes_no_lvh_message">Left Ventricular Hypertrophy not present</string>
    <string name="estes_probable_lvh_message">Probable Left Ventricular Hypertrophy</string>
    <string name="estes_definite_lvh_message">Definite Left Ventricular Hypertrophy</string>
    <string name="estes_key">Left ventricular strain = ST-J point
    depression \u2265 1 mm and inverted T wave in lead V5.  Left
    atrial enlargement = P terminal force in V1 \u2265 1 mm deep and \u2265 40 msec wide.</string>
    <!-- Long QT Subtypes -->
    <string name="lqt_syndrome_title">Long QT Syndrome</string>
    <string name="lqt_syndrome_label">Long QT Syndrome</string>
    <string name="lqt_subtypes_title">Long QT Syndromes (Common)</string>
    <string name="lqt_subtypes_1_name">LQTS 1</string>
    <string name="lqt_subtypes_1_description" tools:ignore="Typos">Frequency: 30-35%\nLocus: 11p15.5\nGene: KVLQT1 (KCNQ1)\nChannel:
        IKs\nECG: Broad T wave\nFeatures: Episodes with stress, exercise, swimming, diving; failure
    	of QT to shorten with exercise</string>
    <string name="lqt_subtypes_2_name">LQTS 2</string>
    <string name="lqt_subtypes_2_description">Frequency: 25-30%\nLocus: 7q35-36\nGene: HERG\nChannel:
    	IKr\nECG: Split or low amplitude late T wave\nFeatures: Triggered by loud noises, alarms</string>
    <string name="lqt_subtypes_3_name">LQTS 3</string>
    <string name="lqt_subtypes_3_description">Frequency: 5-10%\nLocus: 3p21-24\nGene: SCN5A\nChannel:
        INa\nECG: Late onset biphasic or peaked T wave\nFeatures: Associated with bradycardia</string>
    <string name="lqt_subtypes_4_name">LQTS 4</string>
    <string name="lqt_subtypes_4_description">Frequency: 1-2%\nLocus: 4q25-27\nGene: ANKB\nChannel:
    	INaKATP, INaCa exchange\nECG: Variable QT prolongation\nFeatures: No specific features</string>
    <string name="lqt_subtypes_5_name">LQTS 5 – 11</string>
    <string name="lqt_subtypes_5_description" tools:ignore="StringFormatInvalid">Remaining subtypes all &lt;1% frequency (some just single families)
   	    without distinguishing features.  One exception is LQTS 8 which affects the ICaL channel, has
   	    alternating T waves on ECG, and is associated with Timothy Syndrome.</string>
    <string name="lqt_subtypes_reference">\nReferences:\nhttp://www.geneticheartdisease.org/lqts_gene_table.htm\n\nhttp://en.ecgpedia.org/wiki/Long_QT_Syndrome</string>
    <string name="lqt_ecg_title">Long QT ECG Patterns</string>
    <string name="brugada_ecg_title">Brugada ECG Patterns</string>
    <string name="text_label">Notes</string>
    <string name="brugada_ecg_description_title">Brugada Syndrome\nST-T Abnormalities in V1-V3</string>
    <string name="brugada_ecg_description">Type 1: Coved ST elevation with \u2265 2 mm
        J-point elevation and gradually descending ST segment followed by negative T wave.  Considered
        diagnostic of Brugada syndrome if occurs spontaneously or induced by drug challenge.\n\nType 2: 
        Saddle back pattern with \u2265 2 mm J-point elevation and \u2265
        1 mm ST elevation with a positive or biphasic T wave.  Occasionally seen in healthy
        subjects.\n\nType 3: Saddle back pattern 
        with &lt; 2 mm J point elevation and &lt;
        1 mm ST elevation with positive T wave.  Not uncommon in healthy subjects.</string>
    <string name="brugada_ecg_reference">Wilde AAM, Antzelevitch C, Borggrefe M,
        et al. Proposed Diagnostic Criteria for the Brugada Syndrome.
        Circulation. 2002;106(19):2514-2519.</string>
    <string name="brugada_ecg_link">https://doi.org/10.1161/01.CIR.0000034169.45752.4A</string>
    <string name="brugada_diagnosis_reference">Priori SG, Wilde AA, Horie M,
        et al. HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and
        Management of Patients with Inherited Primary Arrhythmia Syndromes:
        Document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA,
        PACES, and AEPC in June 2013. Heart Rhythm. 2013;10(12):1932-1963.</string>
    <string name="brugada_diagnosis_link">https://doi.org/10.1016/j.hrthm.2013.05.01 </string>
    <string name="calculator_list_title">Calculators</string>
    <string name="calculator_title">Calculators</string>
    <string name="diagnosis_list_title">Diagnosis</string>
    <string name="diagnosis_title">Diagnosis</string>
    <string name="reference_list_title">Reference &amp; Tools</string>
    <string name="reference_title">Reference &amp; Tools</string>
    <string name="error_dialog_title">Error</string>
    <string name="estes_contradiction_message">You have selected strain pattern
	    with and without digitalis.  Please select one or the other, not both.</string>
    <string name="day_label">Day</string>
    <string name="sun_label">SUN</string>
    <string name="mon_label">MON</string>
    <string name="tue_label">TUE</string>
    <string name="wed_label">WED</string>
    <string name="thu_label">THU</string>
    <string name="fri_label">FRI</string>
    <string name="sat_label">SAT</string>
    <string name="total_label">TOTAL</string>
    <string name="ah">AH</string>
    <string name="ah_normal">50–125 msec</string>
    <string name="hv">HV</string>
    <string name="hv_normal">35–55 msec</string>
    <string name="h_duration">H duration</string>
    <string name="h_duration_normal">10–25 msec</string>
    <string name="sact">SACT</string>
    <string name="sact_normal">45–125 msec</string>
    <string name="csnrt">Corrected SNRT</string>
    <string name="csnrt_normal">&lt;550 msec</string>
    <string name="srt_scl">SNRT/SCL%</string>
    <string name="srt_scl_normal">&lt;150%</string>
    <string name="aerp">Atrial ERP</string>
    <string name="aerp_normal">170–300 msec</string>
    <string name="avn_bcl">AV Node Block CL</string>
    <string name="avn_bcl_normal">350–500 msec</string>
    <string name="avn_erp">AV Node ERP</string>
    <string name="avn_erp_normal">230–425 msec</string>
    <string name="avn_frp">AV Node FRP</string>
    <string name="avn_frp_normal">300–525 msec</string>
    <string name="hps_erp">HPS ERP</string>
    <string name="hps_erp_normal">330–450 msec</string>
    <string name="verp">Ventricular ERP</string>
    <string name="verp_normal">170–290 msec</string>
    <string name="step_1" tools:ignore="Typos">Step1</string>
    <string name="vt_list_title">Ventricular Tachycardia</string>
    <string name="epicardial_vt_title">Epicardial vs Endocardial VT</string>
    <string name="outflow_tract_vt_title">Outflow Tract VT Location</string>
    <string name="mitral_annular_vt_title">Mitral Annular VT Location</string>
    <string name="epivt_text" formatted="false">Pseudo-delta wave (\u0394): Measured from earliest
        ventricular activation to the earliest fast deflection in any 
        precordial lead. Pseudo-delta wave \u2265 34 msec predicts epicardial origin 
        (Sens 83%, Spec 95%).\n\nIntrinsicoid deflection time (ID): Measured from 
        earliest ventricular activation to
        the peak of the R wave in V2. ID of \u2265 85 msec predicts epicardial origin
        (Sens 87%, Spec 90%).\n\nShortest RS complex (RS): Measured from the earliest
        ventricular activation to the nadir of the first S wave in any precordial lead.
        RS \u2265 121 msec predicts epicardial origin (Sens 76%, Spec 85%).\n\nReference:
        http://circ.ahajournals.org/content/109/15/1842.full</string>
    <string name="outflow_vt_late_transition_step">QRS transition (first precordial lead with R > S) V4 or later?</string>
    <string name="outflow_vt_free_wall_step">QRS duration \u2265 140 msec or R wave notching in inferior leads?</string>
    <string name="outflow_vt_anterior_location_step">Negative or isoelectric QRS in I?</string>
    <string name="outflow_vt_caudal_location_step">Positive or isoelectric QRS in aVL?</string>
    <string name="outflow_vt_v3_transition_step">QRS transition in V3?</string>
    <string name="outflow_vt_indeterminate_location_step">VT location may be right or left sided.  Select
        RV to find predicted RV location, LV to find predicted LV location.</string>
    <string name="outflow_vt_supravalvular_step">Absent S in V5 or V6?</string>
    <string name="outflow_vt_location_label">Ventricular Tachycardia Location</string>
    <string name="rv_label">RV</string>
    <string name="lv_label">LV</string>
    <string name="rvot_label">Right Ventricular Outflow Tract</string>
    <string name="lvot_label">Left Ventricular Outflow Tract</string>
    <string name="cusp_vt_label">\nSupravalvular (aortic cusp) Location.\nTransition 
        is in V2 or V3 with origin in the right coronary cusp, and in V1 or V2 in the left coronary cusp.
        Left coronary cusp VT is often associated with a W- or M-shaped pattern in V1.</string>
    <string name="mitral_annular_vt_label">\nSubvalvular Location.\nVT from the aorto-mitral 
        continuity often has a qR pattern in V1.  VT from the mitral annulus has an R in V1.</string>
    <string name="indeterminate_location">Location cannot be determined.</string>
    <string name="outflow_vt_instructions">Ventricular tachycardia and premature ventricular complexes
 		can arise from either the right
        or left ventricular outflow tract (RVOT or LVOT).  Outflow tract VT has a vertical axis and
        a left bundle branch block pattern in the precordial leads.  The earlier the precordial transition lead,
        the more likely the VT is from the LVOT.  If the precordial transition is in lead V3
        it is not possible to use an algorithm to determine from which ventricle the VT arises.
        See Tanner et al. JACC 2005;45:418. http://content.onlinejacc.org/cgi/content/short/45/3/418.
        \nThis algorithm was developed from Joshi S and Wilber DJ, J Cardiovasc Electrophysiol 2005;16:Suppl I:S52,
        Bala R and Marchlinski FE, Heart Rhythm 2007;4:366, and Srivathsan K et al. Indian Pacing Electrophysiol J
        2005;5:106. http://cogprints.org/4219/1/srivathsan.htm</string>
    <string name="mitral_annular_vt_instructions" formatted="false"> Use this module to predict the
		location of idiopathic mitral annular ventricular tachycardia or premature ventricular complexes based on the ECG.  Note that this module does not deal with
		mitral isthmus VT in the setting of inferior infarction (see Wilber D et al. Circulation 1995;92:3481
		http://circ.ahajournals.org/content/92/12/3481.long)
		Reference: Tada H et al.  JACC 2005;45:877.</string>
    <string name="mavt_initial_step">Precordial transition (first precordial lead with R > S) in V1 or V2
	    with R or Rs pattern in V2 to V5 (R/S > 3 in V2-V4)?</string>
    <string name="mavt_positive_qrs_inferior_leads_step">Positive QRS in inferior leads?</string>
    <string name="mavt_notching_r_inferior_leads_step">Notching of R wave in inferior leads?</string>
    <string name="mavt_notching_q_inferior_leads_step">Notching of Q wave in inferior leads,
        no Q or S wave in V1, and transition in V1?</string>
    <string name="mavt_anterolateral_label">Anterolateral Mitral Annulus</string>
    <string name="mavt_anteromedial_label">Anteromedial Mitral Annulus</string>
    <string name="mavt_posterior_label">Posterior Mitral Annulus</string>
    <string name="mavt_posteroseptal_label">Posteroseptal Mitral Annulus</string>
    <string name="mavt_not_mitral_annular_label">QRS morphology suggests VT or PVCs are NOT
        arising from the mitral annulus</string>
    <string name="sotalol_calculator_title">Sotalol Calculator</string>
    <string name="sotalol_dosing_message">This is the recommended starting dose for treatment of atrial fibrillation.
        Initial QT should be &lt; 450 msec (package insert specifies QT, not QTc).  If QT remains &lt; 500 msec
        dose can be increased to 120 mg or 160</string>
    <string name="warfarin_instructions">This calculator can be used to adjust the 
		warfarin dose when a patient is on a stable weekly dosing schedule.  
		It should not be used when first starting warfarin.  Select the tablet dose 
		the patient uses and the target INR.  Enter the measured INR and the total 
		number of mg the patient is taking per week (e.g. a patient taking 5 mg daily 
		takes 5 x 7 = 35 mg of warfarin per week).  The calculator will determine 
		the percentage weekly dose increase or decrease that is likely to bring the 
		INR back into the target range.  When it is feasible, the calculator will 
		suggest the number of tablets to take each day of the week to achieve the INR goal.  
		An upper and lower range of dosing will be given; in some cases, 
		when dosing changes are small, the upper and lower range will be identical.  
		When there is a range of doses, you might decide to use the higher or 
		lower dose depending on other factors, such as the patient\'s previous response 
		to dosing changes or the patient\'s age.  Warfarin dosing is not an exact science!</string>
    <string name="default_creatinine_unit_title">Default Creatinine Unit</string>
    <string name="default_creatinine_unit_summary">Select default unit for creatinine</string>
    <string name="creatinine_mg_per_dl">Cr (mg/dL)</string>
    <string name="creatinine_mmol_per_l">Cr (\u00B5mol/L)</string>
    <string name="creatinine_mg_hint">Creatinine (mg/dL)</string>
    <string name="creatinine_mmol_hint">Creatinine (\u00B5mol/L)</string>
    <string name="entrainment_title">Entrainment Mapping</string>
    <string name="long_qt_drugs_title">Long QT Drugs (link)</string>
    <string name="long_qt_drugs_link">https://www.crediblemeds.org</string>
    <string name="brugada_drugs_title">Brugada Drugs (link)</string>
    <string name="brugada_drugs_link">https://www.brugadadrugs.org</string>
    <string name="apixaban_calculator_title">Apixaban Calculator</string>
    <string name="apixaban_drug_interaction_at_5_mg_message">Use 2.5 mg twice daily when administered with
        strong dual inhibitors of CYP3A4 and P-gp.</string>
    <string name="apixaban_dual_inhibitors">(e.g. ketoconazole, itraconazole, ritonavir, clarithromycin)</string>
    <string name="apixaban_drug_interaction_at_2_5_mg_message">Avoid coadministration with strong dual inhibitors of CYP3A4 and P-gp.</string>
    <string name="invalid_warning">Invalid!</string>
    <string name="pediatric_use_warning">Pediatric dosing is not recommended or not calculated.
  	    by EP Mobile.</string>
    <string name="do_not_use_warning">Do not use!</string>
    <!-- Atrial tachycardia algorithm Kistler PM et al. -->
    <string name="atrial_tachycardia_localization_title">Atrial Tachycardia Location</string>
    <string name="at_v1_morphology_label">P Wave Morphology in Lead V1?</string>
    <string name="neg_label">Neg</string>
    <string name="pos_neg_label">Pos/Neg</string>
    <string name="neg_pos_label">Neg/Pos</string>
    <string name="iso_pos_label">Iso/Pos</string>
    <string name="iso_label">Iso</string>
    <string name="pos_label">Pos</string>
    <string name="location_ct">Crista Terminalis</string>
    <string name="location_r_septum_perinodal">Right Side of Septum or Perinodal</string>
    <string name="location_sma">Superior Mitral Annulus</string>
    <string name="location_cs_os_ls">Coronary Sinus Os or Left Side of Septum</string>
    <string name="location_ta">Tricuspid Annulus</string>
    <string name="location_ta_raa">Tricuspid Annulus or Right Atrial Appendage</string>
    <string name="location_cs_body">Coronary Sinus Body</string>
    <string name="location_lpv_laa">Left Sided Pulmonary Vein or Left Atrial Appendage</string>
    <string name="location_ct_rpv">Crista Terminalis or Right Sided Pulmonary Vein</string>
    <string name="location_rpv">Right Sided Pulmonary Vein</string>
    <string name="v24_pos_step">P Wave in Leads V2&#8211;4 Positive?</string>
    <string name="avl_step">aVL Polarity?</string>
    <string name="bifid_II_step">Bifid P in II and/or V1?</string>
    <string name="negative_in_all_inf_leads_step">Negative P in All Inferior Leads?</string>
    <string name="sinus_rhythm_p_wave_step">Sinus Rhythm P Wave Morphology?</string>
    <string name="plus_minus_label">Pos/Neg</string>
    <string name="at_localization_reference"> Kistler PM, Roberts-Thomson Kurt
        C., Haqqani HM, et al. P-Wave Morphology in Focal Atrial Tachycardia.
        Journal of the American College of Cardiology. 2006;48(5):1010-1017.</string>
    <string name="at_localization_link">https://doi.org/10.1016/j.jacc.2006.03.058</string>
    <string name="at_localization_instructions">This algorithm applies only to focal atrial tachycardia.
        To be accurate, the P wave must have a discrete isoelectric segment before its start, i.e. don\'t use
        a P wave that is fused onto the end of a T wave.  Iso means isoelectric, defined as a &lt; 0.05 mV
        deviation from the baseline.  The algorithm sensitivity in the original study was 93%.</string>
    <string name="date_calculator_title">Date Calculator</string>
    <string name="date_calculator_instructions">Use this calculator to do date arithmetic.
        Set the starting date to the index date (such as today) and then enter the number of days
        in the future or past that you are adding or subtracting.  Turn Subtract days on
        to subtract days from the index date.</string>
    <string name="index_event_label">Index Event Date</string>
    <string name="number_of_days_label">Number of Days</string>
    <string name="number_of_days_hint">Days</string>
    <string name="days_40">40 Days (ICD OK s/p MI)</string>
    <string name="days_90">90 Days (ICD OK s/p revasc or NICM)</string>
    <string name="days_30">30 Days (new H&amp;P needed)</string>
    <string name="date_result_label">Date</string>
    <string name="reverse_time_label">Subtract Days</string>
    <string name="tcl_label">Tachycardia CL</string>
    <string name="ppi_label">Post-Pacing Int</string>
    <string name="s_qrs_label">S-QRS</string>
    <string name="egm_qrs_label">EG-QRS</string>
    <string name="concealed_fusion_label">Concealed Fusion</string>
    <string name="tcl_hint">TCL (msec)</string>
    <string name="ppi_hint">PPI (msec)</string>
    <string name="s_qrs_hint">S-QRS (msec)</string>
    <string name="egm_qrs_hint">EG-QRS (msec)</string>
    <string name="short_calculate_label">Calc</string>
    <string name="clear_all_label">Clear All</string>
    <string name="help_label">Help</string>
    <string name="clear_keep_tcl_label">Clear</string>
    <string name="entrainment_instructions">This Entrainment Mapping module is most suited for mapping ischemic
		ventricular tachycardia (VT), but principles of entrainment apply to
		all reentrant arrhythmias.  Entrainment is performed by pacing during
		stable VT (or other reentrant tachycardia) for approximately 8-15 beat
		trains at 20-40 msec shorter than the tachycardia cycle length (TCL).
		Make sure all electrograms are "entrained", i.e. the CL shortens to
		the pacing CL.  The post-pacing interval (PPI) is measured from the
		last pacing stimulus to the next electrogram recorded from the pacing
		site.  Concealed fusion is present if the tachycardia morphology does
		not change during entrainment.  If there is concealed fusion then the
		pacing site is in an area of slow conduction near the critical isthmus
		of the reentry circuit.  During VT if a discrete electrogram (EG) is
		present prior to the QRS onset then the EG-QRS interval can be
		measured.  During entrainment with concealed fusion, if there is a
		delay between the pacing stimulus to onset of the QRS (S-QRS), then
		the site is within the critical isthmus if the S-QRS interval is
		similar to the EG-QRS interval.  In addition the relative location
		within the critical isthmus can be estimated by the ratio of the S-QRS
		to the TCL.  Sites with concealed fusion but long PPI intervals are
		probably adjacent bystander tracts.  Pacing sites within the critical
		isthmus are associated with a much higher chance of successful
		tachycardia termination with ablation than other sites.
        EP Mobile uses the criteria of El-Shalakany et al. to identify
        VT sites with high likelihood of ablation success.</string>
    <string name="entrainment_reference">Stevenson WG et al.
        JACC 1997;29:1180.
        \nhttp://content.onlinejacc.org/article.aspx?articleid=1121699
        \nEl-Shalakany A et al. Circulation 1999;99:2283.\n
        https://doi.org/10.1161/01.cir.99.17.2283</string>
    <string name="entrainment_remote_site_message">Remote site from reentry circuit.</string>
    <string name="entrainment_outer_loop_message">Outer loop of reentry circuit.</string>
    <string name="entrainment_inner_loop_message">Inner loop or isthmus site of reentry circuit.</string>
    <string name="entrainment_bystander_message">Adjacent bystander pathway not in reentry circuit.</string>
    <string name="entrainment_egm_match_message">Similar S-QRS and EG-QRS intervals suggest site in isthmus of reentry circuit.</string>
    <string name="entrainment_egm_no_match_message">Dissimilar S-QRS and EG-QRS intervals suggest site may be an adjacent bystander.</string>
    <string name="ppi_minus_tcl_label">PPI-TCL=</string>
    <string name="exit_site_label">Isthmus exit site.</string>
    <string name="central_site_label">Isthmus central site.</string>
    <string name="proximal_site_label">Isthmus proximal site.</string>
    <string name="entry_site_label">Inner loop site.</string>
    <string name="invalid_sqrs_label">Invalid S-QRS (&gt;TCL) ignored!</string>
    <string name="ibw_calculator_title">Weight Calculator</string>
    <string name="ibw_calculator_instructions">Although the package inserts for the drugs
        included in the drug dose calculators recommend using actual uncorrected body
        weight and the Cockcroft-Gault formula for Creatinine Clearance, some authorities
        feel that using a corrected body weight may be more accurate.\n\nThis
        calculator determines the Ideal Body Weight and Adjusted Body Weight
        from the height, sex, and actual body weight.
        The Adjusted Body Weight formula here uses a correction factor of 0.4,
        which may give a more accurate measurement of Creatinine Clearance than
        other factors.  The formulas are not accurate if the height is less than
        60 inches.\n\nPatients who are underweight (weight &lt; Ideal Body Weight)
        should use actual weight for Creatinine Clearance determination.
        Normal weight patients can use Ideal Body Weight, and overweight
        (defined in this calculator as weight 30% or more over Ideal Body Weight)
        should use the Adjusted Body Weight.</string>
    <string name="ibw_calculator_reference">Winter MA, Guhr KN, Berg GM.
        Impact of various body weights and serum creatinine concentrations
        on the bias and accuracy of the Cockcroft-Gault equation.
        Pharmacotherapy. 2012;32(7):604-612.</string>
    <string name="ibw_calculator_link">https://doi.org/10.1002/j.1875-9114.2012.01098.x</string>
    <string name="height_hint">Height (cm)</string>
    <string name="height_inches_hint">Height (in)</string>
    <string name="ibw_label">Ideal Body Weight (kg)</string>
    <string name="ibw_hint">IBW (kg)</string>
    <string name="ibw_lb_label">Ideal Body Weight (lb)</string>
    <string name="ibw_lb_hint">IBW (lb)</string>
    <string name="abw_label">Adjusted Body Weight (kg)</string>
    <string name="abw_hint">ABW (kg)</string>
    <string name="abw_lb_label">Adjusted Body Weight (lb)</string>
    <string name="abw_lb_hint">ABW (lb)</string>
    <string name="default_height_unit_title">Default Height Unit</string>
    <string name="default_height_unit_summary">Select default unit for height</string>
    <string name="overweight_message" tools:ignore="PluralsCandidate">Actual weight is at least 30%% over Ideal Body Weight.  Recommended weight is Adjusted Body Weight (%s</string>
    <string name="underheight_message">These measurements may not be useful when height is &lt; 60 inches.</string>
    <string name="underweight_message">Actual weight is less than Ideal Body Weight.  Recommended weight is Actual Weight (%s</string>
    <string name="normalweight_message">Weight is in the normal range.  Recommended weight is Ideal Body Weight (%s</string>
    <string name="pound_abbreviation">lb</string>
    <string name="kg_abbreviation">kg</string>
    <string name="syncope_list_title">Syncope Risk Scores</string>
    <string name="syncope_sf_rule_title">San Francisco Rule</string>
    <string name="syncope_martin_title">Martin Algorithm</string>
    <string name="syncope_oesil_score_title">OESIL Score</string>
    <string name="syncope_egsys_score_title">EGSYS Score</string>
    <string name="abnormal_ecg_label">Abnormal ECG (new changes or non-sinus rhythm)</string>
    <string name="sob_label">Shortness of breath</string>
    <string name="low_hct_label">Hematocrit &lt; 30%</string>
    <string name="low_bp_label">Systolic BP &lt; 90 mmHg</string>
    <string name="no_sf_rule_risk_message">No or little risk of serious events at 30 days.</string>
    <string name="high_sf_rule_risk_message" formatted="false">Risk of serious events at 30 days (98% sensitive and 56% specific).</string>
    <string name="syncope_sf_rule_reference">Quinn J et al. Ann Emerg Med 2006 47:448</string>
    <string name="history_vt_label">History of ventricular arrhythmia</string>
    <string name="history_chf_label">History of congestive heart failure</string>
    <string name="age_over_45_label">Age &gt; 45 years</string>
    <string name="history_cv_disease_label">History of cardiovascular disease</string>
    <string name="lack_of_prodrome_label">Lack of prodrome</string>
    <string name="age_over_65_label">Age &gt; 65 years</string>
    <string name="martin_algorithm_reference">Martin TP et al. Ann Emerg Med 1997 29:459</string>
    <string name="oesil_score_reference">Colivicchi F et al. Eur Heart J 2003 24:811</string>
    <string name="palps_before_syncope_label">Palpitations before syncope</string>
    <string name="abnormal_ecg_or_heart_disease_label">Abnormal ECG or heart disease</string>
    <string name="syncope_during_effort_label">Syncope during effort</string>
    <string name="syncope_while_supine_label">Syncope while supine</string>
    <string name="autonomic_prodrome_label">Autonomic prodrome (nausea, vomiting)</string>
    <string name="predisposing_factors_label">Predisposing and/or precipitating factors (warm-crowded place,
        prolonged standing, fear, pain, emotion)</string>
    <string name="egsys_score_reference">Del Rosso A et al. Heart 2008 94:1630</string>
    <string name="vereckei_title">Vereckei aVR Algorithm</string>
    <string name="vereckei_step1_label">Initial R in aVR?</string>
    <string name="vereckei_step2_label">Initial r or q in aVR with width > 40 msec?</string>
    <string name="vereckei_step3_label">Notching on the initial downstroke of a predominantly negative QRS complex in aVR?</string>
    <string name="vereckei_step4_label">Ratio of voltage of initial and final 40 msec of QRS complex in aVR
	    (Vi/Vt) \u2264 1?</string>
    <string name="verecki_reference">Reference: Vereckei A et al. Heart Rhythm 2008 5:89.</string>
    <string name="icd_risk_title">ICD Implantation Risk</string>
    <string name="icd_risk_reference">Reference: Dodson JA et al. JACC 2014 8:788.\n</string>
    <string name="female_sex_label">Female sex</string>
    <string name="admission_reason_label">Reason for admission</string>
    <string name="for_procedure_label">For procedure</string>
    <string name="for_heart_failure_label">For heart failure</string>
    <string name="other_label">Other reason</string>
    <string name="nyha_class_label">NYHA functional class</string>
    <string name="class_one_or_two_label">I/II</string>
    <string name="class_three_label">III</string>
    <string name="class_four_label">IV</string>
    <string name="no_prior_cabg_label">No prior CABG</string>
    <string name="current_dialysis_label">Current dialysis</string>
    <string name="chronic_lung_disease_label">Chronic lung disease</string>
    <string name="abnormal_conduction_label">Abnormal conduction</string>
    <string name="no_abnormal_conduction_label">No</string>
    <string name="yes_lbbb_label">Yes LBBB</string>
    <string name="yes_other_label">Yes other</string>
    <string name="procedure_type_label">Procedure type</string>
    <string name="initial_implant_label">Initial implant</string>
    <string name="generator_replacement_eri_label">Generator replacement for ERI</string>
    <string name="generator_replacement_infection_label">Generator replacement for infection</string>
    <string name="generator_replacement_device_relocation_label">Generator replacement for device relocation</string>
    <string name="generator_replacement_upgrade_label">Generator replacement for upgrade</string>
    <string name="generator_replacement_malfunction_label">Generator replacement for malfunction</string>
    <string name="generator_replacement_other_label">Generator replacement for other reason</string>
    <string name="icd_type_label">ICD type</string>
    <string name="single_chamber_label">Single chamber</string>
    <string name="dual_chamber_label">Dual chamber</string>
    <string name="crt_d_label">CRT-D</string>
    <string name="sodium_label">Sodium (mEq/l)</string>
    <string name="low_sodium_label">&lt; 135</string>
    <string name="normal_sodium_label">135 &#8211;145</string>
    <string name="high_sodium_label">&gt; 145</string>
    <string name="hgb_label">Hemoglobin (gm/dL)</string>
    <string name="low_hgb_label">&lt; 12</string>
    <string name="normal_hgb_label">12 &#8211;14</string>
    <string name="high_hgb_label">&gt; 14</string>
    <string name="bun_label">BUN (mg/dL)</string>
    <string name="low_bun_label">&lt; 20</string>
    <string name="normal_bun_label">20 &#8211;40</string>
    <string name="high_bun_label">&gt; 40</string>
    <string name="incomplete_radio_groups_error">Selection incomplete.  You
        must make a selection from each group.</string>
    <string name="icd_result_title">Risk of In-Hospital Complications</string>
    <string name="reference_label">Reference</string>
    <string name="references_label">References</string>
    <string name="none_label">None</string>
    <string name="chads_label">CHADS\u2082</string>
    <string name="chadsvasc_label">CHA\u2082DS\u2082-VASc</string>
    <string name="hasbled_label">HAS-BLED</string>
    <string name="hemorrhages_label">HEMORR\u2082HAGES</string>
    <string name="estes_criteria_label">Romhilt-Estes LVH score</string>
    <string name="hasbled_short_reference">Pisters R et al. Chest 2010 138:1093</string>
    <string name="hasbled_full_reference">Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ,
		Lip GY. A novel user-friendly score (HAS-BLED) to assess
		1-year risk of major bleeding in patients with
		atrial fibrillation: the Euro Heart Survey. Chest
		[Internet]. 2010 Nov [cited 2014 Jun 6];138(5):1093-100.
		Available from: http://journal.publications.chestnet.org/article.aspx?articleid=1045174"</string>
    <string name="chads_chadsvasc_full_reference">Friberg L, Rosenqvist M, Lip GYH.
        Evaluation of risk stratification schemes for ischaemic stroke and bleeding
        in 182 678 patients with atrial fibrillation:
        the Swedish Atrial Fibrillation cohort study.
        Eur Heart J. 2012;33(12):1500-1510. doi:10.1093/eurheartj/ehr488</string>
    <string name="chads_chadsvasc_short_reference">Friberg L et al. Eur Heart J 2012 33:1500</string>
    <string name="hemorrhages_full_reference">Gage BF, Yan Y, Milligan PE,
	    Waterman AD, Culverhouse R, Rich MW,
   		Radford MJ. Clinical classification schemes for predicting
   		hemorrhage: results from the National Registry of Atrial
   		Fibrillation (NRAF). Am Heart J [Internet]. 2006 [cited 2014 Jun
   		6];151:713-9. Available from:
   		http://www.hematology.fi/system/files/HEMORRHAGES-score.pdf</string>
    <string name="estes_short_reference">Reference: Romhilt DW et al. Am Heart J.1968;75:752.</string>
    <string name="estes_full_reference">Romhilt DW, Estes EH Jr.
        A point-score system for the ECG diagnosis
   		of left ventricular hypertrophy. Am Heart J.
   		1968 Jun;75(6):752-8.</string>
    <string name="hcm_full_reference">McKenna WJ. Behr ER. Hypertrophic cardiomyopathy:
	    management, risk stratification, and prevention of sudden death. Heart
   		[Internet]. 2002 Feb [cited 2014 Jun 6];87(2):169-176. Available
   		from: http://heart.bmj.com/content/87/2/169.full</string>
    <string name="hcm_combined_sus_va_risk_label">Cardiac arrest and/or spontaneous
   	    sustained VT</string>
    <string name="syncope_sf_rule_full_reference">Quinn J, McDermott D, Stiell I,
        Kohn M, Wells G. Prospective validation of the San Francisco Syncope rule
        to predict patients with serious outcomes. 2006 May [cited 2014 Jun
   		6];47(5):448-54. Available from:
   		http://www.annemergmed.com/article/S0196-0644(05)01959-1/abstract</string>
    <string name="syncope_sf_rule_label">SF Rule</string>
    <string name="syncope_martin_full_reference">Martin TP, Hanusa BH, Kapoor WN.
	    Risk stratification of patients with syncope. Ann Emerg Med [Internet].
	    1997 April [cited 2014 Jun 6];29(4):459-66. Available from:
   		http://www.annemergmed.com/article/S0196-0644(97)70217-8/abstract</string>
    <string name="syncope_martin_result_label">1-year severe arrhythmia or arrhythmic death risk</string>
    <string name="syncope_oesil_label">OESIL</string>
    <string name="syncope_oesil_full_reference">Colivicchi F, Ammirati F, Melina D,
        Guido V, Imperoli G, Santini M, for the OESIL (Osservatorio Epidemiologico
        sulla Sincope nel Lazio) Study Investigators. Development and prospective
        validation of a risk stratification system for patients with syncope in the
   		emergency department: the OESIL risk score. Eur Heart J
   		[Internet]. 2003 [cited 2014 Jun 6];24:811-19. Available from:
   		http://eurheartj.oxfordjournals.org/content/24/9/811.full.pdf</string>
    <string name="syncope_egsys_label">EGSYS</string>
    <string name="syncope_egsys_full_reference">Del Rosso A, Ungar A, Maggi R,
   	    Giada F, Petix NR, De Santo T, Menozzi C, Brignole M. Clinical predictors
   	    of cardiac syncope at initial evaluation in patients referred urgently to
   	    a general hospital: the EGSYS score. Heart [Internet]. 2008 Dec [cited 2014
   		Jun 6];94(12):1620-6. Available from:
   		http://heart.bmj.com/content/94/12/1620.abstract</string>
    <string name="rva_vs_rvb_pacing_title">RV Apex vs Base Pacing</string>
    <string name="para_hisian_pacing_title">Para-Hisian Pacing</string>
    <string name="qtc_formula_key">qtc_formula</string>
    <string name="maximum_qtc_key">maximum_qtc</string>
    <string name="qtc_formula_default_value">BAZETT</string>
    <string name="interval_rate_default_value">RATE</string>
    <string name="interval_rate_key">interval_rate</string>
    <string name="warfarin_tablet_default_value">2</string>
    <string name="warfarin_tablet_key">default_warfarin_tablet</string>
    <string name="inr_target_default_value">0</string>
    <string name="inr_target_key">default_inr_target</string>
    <string name="weight_unit_default_value">KG</string>
    <string name="weight_unit_key">default_weight_unit</string>
    <string name="height_unit_default_value">CM</string>
    <string name="height_unit_key">default_height_unit</string>
    <string name="creatinine_unit_default_value">MG</string>
    <string name="creatinine_clearance_unit_key">default_creatinine_unit</string>
    <string name="msec">msec</string>
    <string name="no_default_qtc_selected_error_message">No entry (440 msec will be used)</string>
    <string name="edoxaban_calculator_title">Edoxaban Calculator</string>
    <string name="davila_title">D\'Avila Algorithm</string>
    <string name="davila_step_1">Note that this algorithm uses QRS polarity, not delta wave polarity!\n\n
        Polarity of QRS in Lead V1 is + or \u00b1 ?</string>
    <string name="davila_positive_iii">Lead III polarity + ?</string>
    <string name="davila_plus_minus_iii">Lead III polarity \u00b1 ?</string>
    <string name="lp_location">Left Posterior</string>
    <string name="psma_location">Left Posteroseptal (Posteroseptal Mitral Annulus)</string>
    <string name="davila_positive_avl">Lead aVL polarity + ?</string>
    <string name="davila_qrs_pattern">Lead III has Qrs pattern\n
    (deep Q followed by small r and s in a negative QRS complex in lead III)?</string>
    <string name="davila_positive_ii">Lead II polarity + ?</string>
    <string name="davila_positive_v2">Lead V2 polarity + ?</string>
    <string name="davila_ps_location">Posteroseptal</string>
    <string name="davila_rps_location">Right Posteroseptal (Posteroseptal Tricuspid Annulus)</string>
    <string name="davila_ms_location">Mid-septal (Mid-septal Tricuspid Annulus</string>
    <string name="creatinine_clearance_calculator_title">Creatinine Clearance</string>
    <string name="drug_reference_title">Drug Reference</string>
    <string name="rvh_title">Right Ventricular Hypertrophy</string>
    <string name="apixaban">Apixaban</string>
    <string name="dabigatran">Dabigatran</string>
    <string name="dofetilide">Dofetilide</string>
    <string name="edoxaban">Edoxaban</string>
    <string name="rivaroxaban">Rivaroxaban</string>
    <string name="sotalol">Sotalol</string>
    <string name="drug_dose_disclaimer">\nMore information can be found in the Drug Reference
        modules.</string>
    <string name="af_drug_dose_disclaimer">\nDoses calculated here are only for the nonvalvular
        atrial fibrillation indication.</string>
    <string name="apixaban_esrd_caution">\nUse with caution in patients with ESRD on dialysis</string>
    <string name="short_creatinine_clearance_label">CrCl</string>
    <string name="hcm_scd_esc_score_title">HCM SCD Risk (2014)</string>
    <string name="hcm_scd_esc_score_instructions" formatted="false">This risk score calculates the 5 year
        risk of sudden cardiac death in patients with hypertrophic cardiomyopathy.
        See the Key menu item for exact definitions of the parameters.
        ICD implantation is recommended if the risk is \u2265 6% and ICD implantation can
        be considered if the risk is \u2265 4%.
    </string>
    <string name="hcm_scd_key">Age = age at evaluation.\nWall thickness
        = maximum left ventricular wall thickness.  Note all echo measurements via transthoracic echo.
        LA (left atrial) diameter measured in parasternal long axis.\nGradient
        = maximum left ventricular outflow tract gradient determined at
        rest and with Valsalva using pulsed and continuous wave Doppler from the apical 3 and
        5 chamber views. Peak outflow gradients determined by modified Bernoulli equation:
        Gradient = 4V\u00B2, where V is the peak aortic outflow velocity.\nFamily hx of SCD
        = history of sudden cardiac death in 1 or more first degree
        relatives under 40 years old or in a first degree relative with confirmed HCM at
        any age.\nNSVT
        = nonsustained ventricular tachycardia: 3 consecutive ventricular beats
        at a rate of 120 bpm or more and &lt;30 sec duration on Holter monitoring (minimum 24 hrs) at or prior to evaluation.</string>
    <string name="hcm_scd_reference_1">2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
        | European Heart Journal | Oxford Academic.</string>
    <string name="hcm_scd_link_1">https://academic.oup.com/eurheartj/article/35/39/2733/853385#sec-16</string>
    <string name="hcm_scd_reference_2">O’Mahony C, Jichi F, Pavlou M, et al.
        A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy
        (HCM Risk-SCD). European Heart Journal. 2014;35(30):2010-2020.</string>
    <string name="hcm_scd_link_2">https://doi.org/10.1093/eurheartj/eht439</string>
    <string name="age_in_years_label">Age in years</string>
    <string name="age_in_years_hint">Age (yr)</string>
    <string name="max_lv_wall_thickness_hint">Thickness (mm)</string>
    <string name="max_lv_wall_thickness_label">Wall thickness (mm)</string>
    <string name="max_lvot_gradient_label">Gradient (mmHg)</string>
    <string name="max_lvot_gradient_hint">Grad (mmHg)</string>
    <string name="la_size_label">LA diameter (mm)</string>
    <string name="la_size_hint">LA (mm)</string>
    <string name="scd_in_family_label">Family hx of SCD</string>
    <string name="invalid_entries_message">One or more entries are invalid.</string>
    <string name="invalid_age_message">Age must be between 16 and 115 yrs.</string>
    <string name="invalid_thickness_message">Maximum LV wall thickness must be between 10 and 35 mm.</string>
    <string name="invalid_gradient_message">Maximum LV gradient must be between 2 and 154 mmHg.</string>
    <string name="invalid_diameter_message">Maximum LA diameter must be between 28 and 67 mm.</string>
    <string name="icd_not_indicated_message">ICD generally not indicated.</string>
    <string name="icd_may_be_considered_message">ICD may be considered.</string>
    <string name="icd_should_be_considered_message">ICD should be considered.</string>
    <string name="hcm_scd_2014_full_reference" tools:ignore="Typos">O\'Mahony C., Jichi F., Pavlou M.,
        Monserrat L., Anastasakis A., Rapezzi C.  A novel clinical risk prediction
        model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD).
        Eur Heart J [Internet] 2014 Aug [cited 2015 May 29];35(30):2010–2020.
        Available from: http://doi.org/10.1093/eurheartj/eht439
    </string>
    <string name="same_tt2r2_title">SAMe-TT\u2082R\u2082 Score</string>
    <string name="atria_bleeding_score_title">ATRIA Bleeding Risk Score</string>
    <string name="atria_stroke_score_title">ATRIA Stroke Risk Score</string>
    <string name="atria_anemia_label">Anemia (Hgb &lt;13 g/dL M, &lt;12 g/dL F)</string>
    <string name="atria_renal_disease_label">Severe renal disease (GFR &lt;30 mL/min
        or hemodialysis)</string>
    <string name="atria_prior_hemorrhage_label">Any prior hemorrhage</string>
    <string name="atria_htn_label">Diagnosed hypertension</string>
    <string name="atria_bleed_short_reference">Fang MC et al. JACC 2011 58:395</string>
    <string name="atria_bleed_full_reference">Fang MC, Go, AS, Chang Y, Borowsky LH, Pomernacki NK,
        Udaltsova N, Singer DE.  A new risk scheme to predict warfarin-associated
        hemorrhage.  The ATRIA Study.  J Am Coll Cardiol [Internet]. 2011 Jul 2011
        [cited 2015 Nov 29];58(4):395-401.  Available from:
        http://content.onlinejacc.org/article.aspx?articleid=1146658</string>
    <string name="atria_bleed_risk_label">ATRIA bleeding risk</string>
    <string name="low_atria_bleed_message">Low bleeding risk on warfarin
        (hemorrhage rate 0.8% per year).</string>
    <string name="medium_atria_bleed_message">Intermediate bleeding risk on
        warfarin (hemorrhage rate 2.6% per year).  Consider alternatives
        to warfarin.</string>
    <string name="high_atria_bleed_message">High bleeding risk on warfarin
        (hemorrhage rate 5.8% per year).  Strongly consider alternatives
        to warfarin.</string>
    <string name="atria_stroke_short_reference">Singer DE et al.
        J Am Heart Assoc 2013 2:e000250</string>
    <string name="atria_stroke_full_reference">Singer DE, Chang Y, Borowsky LH,
        Fang MC, Pomernacki NK, Udaltsova N, Reynolds K, Go AS.  A new risk scheme to predict
        ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study
        stroke risk score.  J Am Heart Assoc [Internet].  2013 Jun 19 [cited 2015 Nov
        29];2:e000250.  Available from:
        http://jaha.ahajournals.org/content/2/3/e000250</string>
    <string name="atria_stroke_age_85">Age 85 or greater</string>
    <string name="atria_stroke_age_75">Age 75 to 84</string>
    <string name="atria_stroke_age_65">Age 65 to 74</string>
    <string name="atria_stroke_age_less_than_65">Age less than 65</string>
    <string name="atria_stroke_htn_label">Hypertension</string>
    <string name="atria_stroke_proteinuria_label">Proteinuria</string>
    <string name="atria_stroke_renal_disease_label">eGFR &lt; 45 mL/min/1.73 m\u00B2
        or ESRD</string>
    <string name="atria_prior_stroke_label">Prior stroke</string>
    <string name="no_age_checked_message">Select an age range.</string>
    <string name="atria_stroke_risk_label">ATRIA stroke risk</string>
    <string name="low_atria_stroke_message">Low thromboembolic risk
        (&lt;1% per year).</string>
    <string name="medium_atria_stroke_message">Moderate thromboembolic risk
        (1 to &lt;2% per year).</string>
    <string name="high_atria_stroke_message">High thromboembolic risk
        (2% or greater per year).</string>
    <string name="same_med_hx_label">Medical hx (&gt; 2 of HTN, DM,
        CAD/MI, PAD, CHF, prior stroke, pulmonary disease, and hepatic or renal disease)</string>
    <string name="same_treatment_label">Treatment: interacting drugs,
        e.g. amiodarone</string>
    <string name="same_smoking_label">Tobacco use (within 2 y)</string>
    <string name="same_race_label">Race (non-Caucasian)</string>
    <string name="same_sex_label">Sex (female)</string>
    <string name="same_age_label">Age (&lt;60 y)</string>
    <string name="same_short_reference">Apostolakis S et al.
        Chest 2013;144:1555</string>
    <string name="same_full_reference">Apostolakis S, Sullivan RM, Olshansky B,
        Lip GYH.  Factors affecting quality of anticoagulation control among
        patients with atrial fibrillation on warfarin.  The
        SAMe-TT\u2082R\u2082 Score.  Chest [Internet].  2013 Nov
        [cited 2015 Dec 2] 144(5):1555-1563.  Available from:
        http://journal.publications.chestnet.org/article.aspx?articleid=1686270</string>
    <string name="same_risk_label">SAMe-TT\u2082R\u2082</string>
    <string name="low_same_risk_message">Patient likely to have good
        anticoagulation control on warfarin with high (\u226565%) TTR
        (Time in Therapeutic Range).</string>
    <string name="high_same_risk_message">Patient likely to have poor
        anticoagulation control on warfarin with low
        (&lt;65%) TTR (Time in Therapeutic Range).
        Improve education regarding anticoagulation control,
        or consider a new oral anticoagulant instead of warfarin.</string>
    <string name="orbit_anemia_label">Anemia or hx anemia (Hgb &lt; 13 mg/dL male, &lt; 12 mg/dL female></string>
    <string name="orbit_bleeding_label">Bleeding hx</string>
    <string name="orbit_renal_insufficiency_label">Renal insufficiency (eGFR &lt; 60 mg/dL/1.73 m²)</string>
    <string name="orbit_antiplatelet_label">Antiplatelet drug treatment</string>
    <string name="orbit_label">ORBIT</string>
    <string name="low_orbit_message">Low bleeding risk.</string>
    <string name="medium_orbit_message">Medium bleeding risk.</string>
    <string name="high_orbit_message">High bleeding risk.</string>
    <string name="orbit_full_reference">O\'Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE,
        Kowey PR, Mahaffey KW, Chang P, Fonarow GC, Pencina MJ, Piccini JP, Peterson ED.
        The ORBIT Bleeding Score: A Simple Bedside Score to Assess Bleeding Risk in Atrial Fibrillation.
        Eur Heart J [Internet].  2015 [cited 2016 Mar 13] 36(46):3258-3264.
        Available from: http://www.medscape.com/viewarticle/855941_1</string>
    <string name="orbit_short_reference">O\'Brien EC et al.  Eur Heart J 2016;36:3258</string>
    <string name="orbit_risk_title">ORBIT Bleeding Risk Score</string>
    <string name="qrs_label">QRS (msec)</string>
    <string name="qrs_hint">QRS (msec)</string>
    <string name="sex_label">Sex</string>
    <string name="lbbb_query">LBBB?</string>
    <string name="qtc_ivcd_calculator_title">QTc With IVCD</string>
    <string name="qtc_ivcd_results_title">QTc with IVCD Results</string>
    <string name="qt_calculator_error">One or more values are incorrect or missing.</string>
    <string name="qt_ivcd_info_message">Select any result for more details</string>
    <string name="prelbbbqtc_lbbb_error_message">preLBBB QTc only defined for LBBB</string>
    <string name="qt_details" tools:ignore="PluralsCandidate">QT = %d msec.\n\nUse: The QT varies with heart rate,
        QRS and sex, and so is usually not a good measure of repolarization independent
        of these other factors.\n\nFormula:
        This is the uncorrected QT interval.\n\nNormal values: Not defined</string>
    <string name="qtc_details" tools:ignore="PluralsCandidate">QTc = %1$d msec.\n\nUse: The QTc corrects
        for heart rate but does not correct for increased QRS duration.
        \n\nFormula: %2$s\n\nNormal values (without IVCD) per
        AHA/ACC/HRS guidelines
        (%3$s): Male &lt; 450 msec, Female &lt; 460 msec and &gt; 390 msec (both sexes)</string>
    <string name="qtc_limits_reference">Rautaharju PM, Surawicz B, Gettes LS.
        AHA/ACCF/HRS Recommendations for the Standardization and Interpretation
        of the Electrocardiogram Part IV: The ST Segment, T and U Waves,
        and the QT Interval: A Scientific Statement From the American Heart
        Association Electrocardiography and Arrhythmias Committee, Council on
        Clinical Cardiology; the American College of Cardiology Foundation;
        and the Heart Rhythm Society: Endorsed by the International
        Society for Computerized Electrocardiology. Circulation.
        2009;119(10):e241-e250.</string>
    <string name="qtc_limits_short_reference">Rautaharju et al., Circulation.
        2009;119(10):e241-e250.</string>
    <string name="qtc_limits_link">https://doi.org/10.1161/CIRCULATIONAHA.108.191096</string>
    <string name="qt_ivcd_instructions">Select any of the results in the list to see a dialog with detailed results</string>
    <string name="qt_instructions_title">Instructions</string>
    <string name="qt_details_title">Uncorrected QT</string>
    <string name="qtc_details_title">Corrected QT</string>
    <string name="qtc_ivcd_reference_bogossian">Bogossian H, Linz D, 
        Heijman J, et al. QTc evaluation in patients with bundle branch 
        block. Int J Cardiol Heart Vasc. 2020;30:100636.</string>
    <string name="qtc_ivcd_link_bogossian">https://doi.org/10.1016/j.ijcha.2020.100636</string>
    <string name="qtc_ivcd_reference_rautaharju">Rautaharju PM, Zhang ZM,
        Prineas R, Heiss G. Assessment of prolonged QT and JT
        intervals in ventricular conduction defects. American Journal of
        Cardiology. 2004;93(8):1017-1021.</string>
    <string name="qtc_ivcd_link_rautaharju">https://doi.org/10.1016/j.amjcard.2003.12.055</string>
    <string name="qtc_ivcd_reference_yankelson">Yankelson L, Hochstadt A,
        Sadeh B, et al. New formula for defining “normal” and “prolonged”
        QT in patients with bundle branch block. Journal of Electrocardiology.
        2018;51(3):481-486.</string>
    <string name="qtc_ivcd_link_yankelson">https://doi.org/10.1016/j.jelectrocard.2017.12.039</string>
    <string name="qtm_new_reference">Bogossian H, et al.
        QTc evaluation in patients with bundle branch block.
        Int J Cardiol Heart Vasc. 2020;30:100636.</string>
    <string name="qtm_new_details_title">Modified QT (Bogossian)</string>
    <string name="qtmc_new_details_title">Corrected Modified QT (Bogossian)</string>
    <string name="qtrrqrs_formula">QTrr,qrs = QT - 155 x (60/HR - 1)
        - 0.93 x (QRS - 139) + k, k = -22 ms for men and -34 ms for women</string>
    <string name="qtrrqrs_reference">Rautaharju P et al. Assessment of prolonged QT
        and JT intervals in ventricular conduction defects.
        Amer J Cardio 2003;93:1017-1021.</string>
    <string name="jt_details_title">Uncorrected JT</string>
    <string name="jtc_details_title">Corrected JT</string>
    <string name="qtrrqrs_details_title">QT Corrected for Rate,\nQRS, and Sex (QTrr,qrs)</string>
    <string name="jt_details" tools:ignore="PluralsCandidate">JT = %d msec.\n\nUse: The JT interval corrects for QRS duration,
        but does not correct for heart rate.
        \n\nFormula: JT = QT - QRS\n\nNormal values: Not defined.</string>
    <string name="jtc_details" tools:ignore="PluralsCandidate">JTc = %d msec.\n\nUse: JTc corrects for heart rate and QRS duration, however normal values are not well established.
        \n\nFormula: JTc = QTc - QRS\n\nNormal values: Not defined.</string>
    <string name="qtmc_details" tools:ignore="PluralsCandidate">QTmc = %1$d msec.\n\nUse: Corrects QTm for heart rate.
        The recommended correction formulas are HODGES or FRIDERICIA.\n\nFormula: QTmc = QTm corrected
        for rate using %2$s formula.  \n\nNormal values:
        Presumably the same as QTc.\n\nReference: %3$s</string>
    <string name="qtm_details" tools:ignore="PluralsCandidate">QTm = %1$d msec.\n\nUse: Attempts to correct for the
        prolongation of the QT interval attributable to QRS prolongation.
        \n\nFormula: QTm = QTb - 0.50 * QRSb\n\nNormal values:
        Not defined.\n\nReference: %2$s</string>
    <string name="qtrrqrs_details" tools:ignore="PluralsCandidate">QTrr,qrs = %1$d msec.\n\nUse:
        Corrects QT for rate, QRS duration and sex.\n\nFormula: %2$s\n\nNormal values:
        2%% and 5%% normal limits of 460 and 450 msec.\n\nReference: %3$s</string>
    <string name="very_high_risk_label">Very High Risk (BUN \u2265 50 or Cr \u2265 2.5 mg/dL)</string>
    <string name="nyha_greater_than_2_label">NYHA class &gt; II</string>
    <string name="age70_label">Age &gt; 70</string>
    <string name="qrs_greater_than_12_label">QRS &gt; 0.12 sec</string>
    <string name="bun_greater_than_26_label">BUN &gt; 26 mg/dL</string>
    <string name="afb_baseline_label">AFB as baseline rhythm</string>
    <string name="icd_mortality_risk_full_reference">Goldenberg I, Vyas AK, Hall WJ,
        Moss AJ, Wang H, He H, Zareba W, McNitt S, Andrews ML, MADIT-II Investigators.
        Risk stratification for primary implantation of a cardioverter-defibrillator
        in patients with ischemic left ventricular dysfunction.
        J Am Coll Cardiol [Internet] 2008 Jan [cited 2016 Sep 1];51(3):288-296.
        Available from
        http://content.onlinejacc.org/article.aspx?articleid=1187155</string>
    <string name="icd_mortality_risk_short_reference">Goldenberg I et al.
        JACC 2008;51:288</string>
    <string name="vhr_message">In the Very High Risk group there is high (50%%) 2 year mortality
        in MADIT-II type patients regardless of therapy (conventional therapy %1$d%%,
        ICD %2$d%% mortality).</string>
    <string name="not_vhr_message">The 2 year mortality risk in MADIT-II type patients with
        conventional therapy is %1$d%%, and with ICD therapy is %2$d%%.</string>
    <string name="icd_mortality_warning_message">Results based on MADIT-II study population, in brief,
        EF \u2264 30%%, prior MI, excluding NYHA class IV, recent MI/CABG,
        renal failure and others.</string>
    <string name="ecg_criteria_label">ECG (12 lead/ambulatory)</string>
    <string name="brugada_family_history_label">Family History</string>
    <string name="genetic_test_result_label">Genetic Test Result</string>
    <string name="spontaneous_type_1_ecg_label">Spontaneous type 1 Brugada ECG pattern at nominal or high leads</string>
    <string name="fever_type_1_ecg_label">Fever-induced type 1 Brugada ECG pattern at nominal or high leads</string>
    <string name="type_2_3_ecg_label">Type 2 or 3 Brugada ECG pattern that converts with provocative drug challenge</string>
    <string name="unexplained_arrest_label">Unexplained arrest or documented VF/polymorphic VT</string>
    <string name="agonal_respirations_label">Nocturnal agonal respirations</string>
    <string name="arrhythmic_syncope_label">Suspected arrhythmic syncope</string>
    <string name="unclear_syncope_label">Syncope of unclear mechanism/unclear etiology</string>
    <string name="afl_afb_label">Atrial flutter/fibrillation in patients &lt; 30 years without alternative etiology</string>
    <string name="relative_definite_brugada_label">First- or second-degree relative with definite Brugada Syndrome</string>
    <string name="suspicious_scd_label">Suspicious SCD (fever, nocturnal, Brugada aggravating drugs) in first- or second-degree relative</string>
    <string name="unexplained_scd_label">Unexplained SCD &lt; 45 years in first- or second-degree relative with negative autopsy</string>
    <string name="pathogenic_mutation_label">Probable pathogenic mutation in Brugada susceptibility gene</string>
    <string name="brugada_score_reference">Antzelevitch C, Yan GX, Ackerman MJ,
        et al. J-Wave syndromes expert consensus conference report: Emerging
        concepts and gaps in knowledge. J Arrhythm. 2016;32(5):315-339.</string>
    <string name="brugada_score_link">https://doi.org/10.1016/j.joa.2016.07.002</string>
    <string name="brugada_score_full_reference">Antzelevitch C, Yan GX, Ackerman
        MJ, et al. J-Wave syndromes expert consensus conference report:
        Emerging concepts and gaps in knowledge. J Arrhythm. 2016;32(5):315-339.
        doi:10.1016/j.joa.2016.07.002</string>
    <string name="brugada_score_key">VF = ventricular fibrillation.
        \nVT = ventricular tachycardia.
        \nSCD = sudden cardiac death.</string>
    <string name="large_er_label">ER ≥ 0.2 mV in ≥ 2 inferior and/or lateral ECG leads with horizontal/descending ST segment (\'IIa pattern\')</string>
    <string name="dynamic_j_point_label">Dynamic changes in J-point elevation (≥ 0.1 mV) in ≥ 2 inferior and/or lateral leads</string>
    <string name="j_point_elevation_label">≥ 0.1 mV J-point elevation in at least 2 inferior and/or lateral ECG leads</string>
    <string name="relative_definite_ers_label">Relative with definite ERS</string>
    <string name="relative_ers_ecg_label">≥ 2 first-degree relatives with a IIa ECG pattern as above</string>
    <string name="one_relative_ers_ecg_label">First-degree relative with a IIa ECG pattern as above</string>
    <string name="ers_pathogenic_mutation_label">Probable pathogenic ERS mutation</string>
    <string name="ambulatory_ecg_label">Ambulatory ECG Monitoring</string>
    <string name="ecg_label">12-lead ECG</string>
    <string name="short_coupled_pvcs_label">Short-coupled PVCs with R on ascending limb or peak of T wave</string>
    <string name="ers_score_key">ER = Early repolarization.  PVCs = Premature ventricular complexes VF = ventricular fibrillation.  VT = ventricular tachycardia.
	    SCD = sudden cardiac death.</string>
    <string name="absolute_exclusions_label">Absolute Exclusions</string>
    <string name="personal_hx_vt_ca_label">Personal history of sustained VT or CA due to VF with:</string>
    <string name="ejection_fraction_label">EF</string>
    <string name="other_indication_label">Other Indications</string>
    <string name="icd_replacement_label">Patient with existing ICD at ERI or with lead/device malfunction</string>
    <string name="icd_transplant_bridge_label">Candidates for heart transplantation on transplant list</string>
    <string name="icd_ef_not_measured_text">Note that all ICD candidates must have left ventricular EF measured by echocardiography,
        radionuclide (nuclear medicine) imaging, cardiac magnetic resonance imaging (MRI), or catheter angiography.
        Select an EF range and try again.</string>
    <string name="icd_no_indications_message">No ICD indications have been selected.  Use the checkboxes to select an indication.</string>
    <string name="icd_exceptions_apply">Waiting periods (CABG or PCI within 3 months, MI within 40 days) do not apply in this
        circumstance.</string>
    <string name="icd_approval_unclear_message">Not enough information to determine if ICD is indicated.</string>
    <string name="icd_approved_after_waiting_period">It is necessary to delay implantation until waiting period expires
        (40 days post-MI, 3 months post CABG or PCI).
        Note that if a pacemaker is indicated or the patient has an ICD at ERI or with lead/device malfunction,
        ICD implantation CAN proceed before waiting period expires.</string>
    <string name="waiting_period_label">Waiting Periods</string>
    <string name="icd_bridge_to_transplant_message">Coverage of ICDs as a bridge to transplant is determined by local Medicare Administrative Contractors (MACs).</string>
    <string name="icd_forgot_to_check_cm_checkbox">You selected MI and patient has Class II or III heart failure.  Did you forget to select ischemic or nonischemic cardiomyopathy?</string>
    <string name="icd_possibly_forgot_to_check_mi_checkbox">You selected ICM and patient has low EF but only Class I heart failure.  Did you forget to select prior MI?</string>
    <string name="icd_revasc_candidate">ICD implantation not indicated in candidate for revascularization.</string>
    <string name="ok_button_label">OK</string>
    <string name="version_string">Version %s</string>
    <string name="etiology_label">Etiology</string>
    <string name="clinical_presentation_label">Clinical Presentation</string>
    <string name="imaging_label">Imaging</string>
    <string name="malignant_disease_label">Malignant disease</string>
    <string name="dyspnea_label">Dyspnea/Tachypnea</string>
    <string name="cardiomegaly_label">Cardiomegaly on CXR</string>
    <string name="tamponade_key">* in the absence of medications affecting heart rate,
        hypothyroidism and uremia.
        IVC = inferior vena cava, PE = pericardial effusion, SBP = systolic blood pressure.
        Contraindications to pericardiocentesis include uncorrected coagulopathy,
	INR &gt; 1.5, thrombocytopenia &lt; 50,000/mm\u00b3, small, posterior, and loculated
	effusions, or effusions resolving under anti-inflammatory treatment.
    </string>
    <string name="tamponade_reference">Risti AD, Imazio M, Adler Y, et al. Triage strategy for
        urgent management of cardiac tamponade: a position statement of the European Society of
        Cardiology Working Group on Myocardial and Pericardial Diseases.
        European Heart Journal. 2014;35(34):2279-2284. https://doi.org/10.1093/eurheartj/ehu217 </string>
    <string name="tuberculosis_label">Tuberculosis</string>
    <string name="recent_radiotherapy_label">Recent radiotherapy</string>
    <string name="recent_viral_infection_label">Recent viral infection</string>
    <string name="recurrent_pe_label">Recurrent PE, previous pericardiocentesis</string>
    <string name="chronic_renal_failure_label">Chronic terminal renal failure</string>
    <string name="immunodeficiency_label">Immunodeficiency or immunosuppression</string>
    <string name="hypo_hyperthyroidism_label">Hypo- or hyperthyroidism</string>
    <string name="autoimmune_disease_label">Systemic autoimmune disease</string>
    <string name="orthopnea_label">Orthopnea (NO rales on lung auscultation)</string>
    <string name="hypotension_label">Hypotension (SBP &lt; 95 mmHg)</string>
    <string name="sinus_tachycardia_label">Progressive sinus tachycardia*</string>
    <string name="oliguria_label">Oliguria</string>
    <string name="pulsus_paradoxus_label">Pulsus paradoxus &gt; 10 mmHg</string>
    <string name="friction_rub_label">Pericardial friction rub</string>
    <string name="chest_pain_label">Pericardial chest pain</string>
    <string name="symptom_worsening_label">Rapid worsening of symptoms</string>
    <string name="slow_evolution_label">Slow evolution of the disease</string>
    <string name="electrical_alternans_label">Electrical alternans on ECG</string>
    <string name="microvoltage_label">Microvoltage in ECG</string>
    <string name="circumferential_pe_label">Circumferential PE (&gt; 2 cm in diastole)</string>
    <string name="moderate_pe_label">Moderate PE (1&#8211;2 cm in diastole)</string>
    <string name="small_pe_label">Small PE (&lt; 1 cm in diastole), no trauma</string>
    <string name="ra_collapse_label">Right atrial collapse &gt; &#8531; of cardiac cycle</string>
    <string name="large_ivc_label">IVC &gt; 2.5 cm, &lt; 50% inspiratory collapse</string>
    <string name="rv_collapse_label">Right ventricular collapse</string>
    <string name="la_collapse_label">Left atrial collapse</string>
    <string name="respiratory_variations_label">Mitral/tricuspid respiratory flow variations</string>
    <string name="swinging_heart_label">Swinging heart</string>
    <string name="urgent_pericardiocentesis_message">Urgent pericardiocentesis immediately after contraindications are ruled-out.</string>
    <string name="postpone_pericardiocentesis_message">Pericardiocentesis can be postponed for up to 12/48 hours.</string>
    <string name="urgent_management_message">NOTE: Urgent surgical management is recommended
        regardless of the score for:\n1. Type A aortic dissection\n2.
        Ventricular free wall rupture after acute myocardial infarction\n3. Severe
        recent chest trauma\n4. Iatrogenic hemopericardium when
        the bleeding cannot be controlled percutaneously</string>
	<string name="prelbbbqtc_details_title">preLBBBQTc</string>
	<string name="prelbbbqtc_details" tools:ignore="PluralsCandidate">preLBBBQTc = %1$d msec.\n\nUse: Attempts to correct for the
        prolongation of the QT interval attributable to QRS prolongation in LBBB.  The original paper used
        the BAZETT formula to determine the postLBBBQTc in the formula below.
        \n\nFormula: preLBBBQTc = postLBBBQTc - postLBBBQRS + c,
        where c = 95 msec in males, 88 msec in females\n\nNormal values:
        Presumably same as QTc.\n\nReference: %2$s</string>
    <string name="prelbbbqtc_reference">Yankelson L, Hochstadt A, Sadeh B, et al. New formula for defining “normal” and “prolonged” QT in patients with bundle branch block. Journal of Electrocardiology. 2018;51(3):481-486. doi:10.1016/j.jelectrocard.2017.12.039
</string>
    <string name="short_qrs_error">QRS duration must be at least 120 msec.</string>
    <string name="arvc_risk_title">ARVC Risk</string>
    <string name="arvc_risk_full_reference">Cardrin-Tourigny J, Bosman LP, Nozza A, et al.
        A new prediction model for ventricular arrhythmias in arrhythmogenic
        right ventricular cardiomyopathy.
        European Heart Journal. Published online April 20, 2022:ehac180. doi:10.1093/eurheartj/ehac180
    </string>
    <string name="age_at_dx_label">Age at diagnosis of ARVC</string>
    <string name="cardiac_syncope_within_6_months_label">Specify if the patient experienced syncope suspected to be caused by cardiac
        arrhythmia in the 6 months prior to diagnosis.</string>
    <string name="cardiac_syncope_label">Cardiac syncope (&lt; 6 months)</string>
    <string name="number_twi_label">Number of inverted T waves</string>
    <string name="number_twi_details">Specify the total number of inverted T-waves in precordial and inferior leads on standard 12-lead ECG.
    </string>
    <string name="max_pvc_count_label">Max 24 hr PVC count</string>
    <string name="hx_nsvt_label">History of NSVT</string>
    <string name="hx_nsvt_details">Specified as a recorded ventricular tachycardia (>100bpm) ending spontaneously within 30 seconds</string>
    <string name="rvef_label">Right ventricular ejection fraction (%)</string>
    <string name="max_pvc_count_details">Enter the maximum number of PVCs measured in 24 hours by ECG/Holter monitoring.</string>
    <string name="pvc_hint">Number of PVCs</string>
    <string name="risk_sus_va_title">Risk of sustained ventricular arrhythmia</string>
    <string name="arvc_age_out_of_range_message">Please enter age at least 14 and at most 90 years old.</string>
    <string name="arvc_age_out_of_range_title">Age out of range</string>
    <string name="arvc_pvc_count_range_error_message">Please enter PVC count less than 100000</string>
    <string name="arvc_pvc_count_range_error_title">PVC count out of range</string>
    <string name="values_range_error_message">Values out of range.</string>
    <string name="data_incomplete_message">Data incomplete.</string>
    <string name="arvc_disclaimer">The calculator should not be used in patients with
    prior sustained ventricular arrhythmia or sudden cardiac arrest.
    It is designed to provide predictions based on the clinical characteristics of
    ARVC patients at time of their diagnosis.</string>
    <string name="rvef_details">As measured by cardiac MRI.</string>
    <string name="long_qt_table_title">Long QT Syndromes (All)</string>
    <string name="qt_prolongation_risk_full_reference">Tisdale James E., Jaynes Heather A., Kingery Joanna R., et al.
        Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients.
        Circulation: Cardiovascular Quality and Outcomes. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152</string>
    <string name="qt_prolongation_risk_short_reference">Tisdale et al., CIRC CV Qual and Outcomes 2013 6:479</string>
    <string name="qt_prolongation_risk_label">QT Prolongation Risk</string>
    <string name="age_factor_label">Age &#8805; 68</string>
    <string name="female_sex_factor_label">Female sex</string>
    <string name="loop_diuretic_factor_label">Loop diuretic</string>
    <string name="serum_k_factor_label">Serum potassium &#8804; 3.5 mEq/L</string>
    <string name="admission_qtc_factor_label">Admission QTc (Bazett) &#8805; 450 msec</string>
    <string name="acute_mi_factor_label">Acute MI</string>
    <string name="sepsis_factor_label">Sepsis</string>
    <string name="heart_failure_label">Heart failure</string>
    <string name="one_qtc_drug_factor_label">One QTc prolonging drug</string>
    <string name="two_qtc_drugs_factor_label">Two or more QTc prolonging drugs</string>
    <string name="qt_prolongation_risk_result_label">Risk of QT Prolongation</string>
    <string name="qt_prolongation_result">QT prolongation risk score =</string>
    <string name="qt_prolongation_result_trailer">of developing QT prolongation during hospitalization.</string>
    <string name="qt_prolongation_low_risk">\nLow risk (~15%)</string>
    <string name="qt_prolongation_mod_risk">\nModerate risk (~37%)</string>
    <string name="qt_prolongation_high_risk">\nHigh risk (~73%)</string>
    <string name="arvc_reference_link">https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehac180/6569858</string>
    <string name="cl_result_as_rate">Rate = %s bpm</string>
    <string name="cl_result_as_interval">Interval = %s msec</string>
    <string name="dc_default_number_of_days">90</string>
    <string name="increase">Increase</string>
    <string name="decrease">Decrease</string>
    <string name="reference_full">\nReference: %s</string>
    <string name="arvc_5_y_risk">%s%% within 5 years\n</string>
    <string name="arvc_2_y_risk">%s%% within 2 years\n</string>
    <string name="arvc_1_y_risk">%s%% within 1 year</string>
    <string name="brugada_score_risk_score">Risk Score = %s\n</string>
    <string name="brugada_score_probable_message">Probable/definite Brugada Syndrome</string>
    <string name="brugada_score_possible_message">Possible Brugada Syndrome</string>
    <string name="nondiagnostic_message">Non-diagnostic</string>
    <string name="dose_table_dose_change">%1$s%% %2$s</string>
    <string name="qtc_formula_used">QTc formula used was %s </string>
    <string name="qtc_result">QTc = %s msec</string>
    <string name="icd_mortality_risk_title">ICD Mortality Risk</string>
    <string name="brugada_syndrome_title">Brugada Syndrome</string>
    <string name="ers_title">Early Repolarization Syndrome</string>
    <string name="brugada_score_title">Brugada Shanghai Score</string>
    <string name="brugada_diagnosis_title">Brugada Diagnosis</string>
    <string name="lbbb_title">Left Bundle Branch Block</string>
    <string name="tamponade_title">Cardiac Tamponade</string>
    <string name="qt_prolongation_risk_title">QT Prolongation Risk</string>
    <string name="warfarin_dose_title">Warfarin Dose (%s mg tabs)</string>
    <string name="entrainment_high_chance_success">\ Site has high chance of ablation success, if ablating VT.</string>
    <string name="non_black_label">Non-black</string>
    <string name="black_label">Black</string>
    <string name="gfr_result_label">GFR</string>
    <string name="gfr_reference">Levey AS, Stevens LA, Schmid CH, et al.
        A new equation to estimate glomerular filtration rate. Ann Intern Med.
        2009;150(9):604-612.</string>
    <string name="gfr_link">https://doi.org/10.7326/0003-4819-150-9-200905050-00006</string>
    <string name="notes_label">Notes</string>
    <string name="error_message">Unexpected error!</string>
    <string name="key_label">Key</string>
</resources>
